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Abstract 
Background 
Uveal melanoma is the most common primary ocular cancer in adults and ~50% of 
patients will develop metastatic disease within I 0 years of diagnosis. Growth and 
development of uveal melanoma involves both cellular and environmental factors. 
Cellular factors including metalloproteinases and their inhibitors (MMPs and TIMPs) and 
CD 146, an immunoglobulin superfamily protein, have been suggested to be involved in 
melanoma growth and invasion. Epidemiological studies have implicated long-term UV 
exposure as a risk factor for developing uveal melanoma. The role(s) of these factors in 
the pathogenesis of uveal melanoma were more comprehensively investigated in this 
thesis. 
Methods 
The expression and distribution of MMP-9, TIMP-3 and CD146 were examined in 
paraffin sections of primary uveal melanomas (n=23; 5/23 spindle; 18/23 mixed and 
epithelioid) and normal eyes (n=3) using immunohistochemistry. The intensity of 
immunostaining was graded semi-quantitatively (grade 0 to 3) by 2 independent 
ob~ervers. For the in vitro studies melanoma cell lines (7 uveal and 3 metastasis-derived) 
were assessed for CD146 mRNA and protein expression using RT-PCR and 
immunoblotting respectively. 
To assess for the effects of UV-B on cell growth and survival, cultures of primary uveal 
melanocytes (Pl-P3) and melanoma cell lines (OCM-1 and OCM-8) were used. Cells 
were exposed to 0-30 mJ/cm2 UV-B, and cell morphology and growth were examined; 
cell viability was assessed using an MIT assay. Gelatin zymography was used to assess 
enzymatic activity for MMPs in conditioned media following UV-B treatment. 
·. 
Results 
Moderate to strong ~ Grade2) cytoplasmic 'MMP-9 immunolabelling was observed in 
74% tumours, with ~ Grade 2 TIMP-3 immunolabelling found in - 50% of tumours. 
Heterogeneous MMP-9 immunolabelling was observed in tumour vasculature, and 
intravascular leukocytes also expressed MMP-9. Groups of tumour cells with intense 
111 
TIMP-3 immunostaining were seen surroundin-g tumour vessels in 5/23 tumours, although 
the vasculature did not express TIMP-3 . 
.. 
Heterogeneous cell membrane and cytoplasmic CD 146 expression was observed, with ~ 
Grade 2 immunostaining seen in ~ 70% of tumours. In primary mixed and epithelioid 
tumour specimens, CD146 immunoreactivity was significantly greater than in spindle cell 
tumours. The vasculature in tumours, and in the retina and choroid of all melanoma and 
normal eyes showed intense CD 146 immunostaining. All cell lines and uveal melanocytes 
expressed CD146 mRNA and protein (-130kDa) but levels of protein varied among 
different cell lines. 
UV-B ~20 mJ/cm2 was cytotoxic for uveal melanocytes. Cytotoxic doses of 5 to 10 
mJ/cm2 were found for OCM-8 and OCM-1 melanoma cell lines respectively. Low levels 
of UV-B (2.5 and 3.5 mJ/cm2) significantly reduced melanoma cell viability after 48 hrs, 
although melanocyte viability was not affected for doses of UV-B <10 mJ/cm2. 
Conditioned media from melanoma cells and melanocytes displayed pro-MMP-2 activity, 
independent of UV-B. Control and UV-B treated OCM-1 cells secreted active MMP-2 up 
to 72 hrs. Pro-MMP-9 was seen from 36 hrs for control and UV-B treated OCM-1 and 
OCM-8 cells. 
Conclusions 
The distinct immunostaining patterns observed within uveal melanoma for MMP-9 and 
TIMP-3 are consistent with their involvement in tumour growth and angiogenesis. In 
particular, the heterogeneous expression within regions of the tumours, and the localized 
expression in vasculature emphasises the importance of the tumour microenvironment in 
the pathogenesis of uveal melanoma. 
The present study indicates that while CD 146 is important for uveal melanoma growth, its 
expression may not be essential for invasion and metastasis, consistent with fmdings in 
other tumours, including cutaneous melanoma. Interactions between CD 146-positive 
melanoma cells and vasculature, via an as yet unidentified ligand, may be important for 
the haematogenous spread of tumour cells during metastases and requires further 
investigation. 
Decreased survival of uveal melanoma cells, but not melanocytes, following low doses of 
UV-B exposure suggests differences in cellular responses to DNA damage that may be 
IV 
important in subsequent transformation of melanocytes to melanoma cells. UV-B did not 
induce the production and/or activation of MMP-2 and -9 in melanocytes or melanoma 
cells, although whether other proteinases may be regulated by UV-B in these cells remains 
to be determined. These observations suggest that the expression of DNA damage 
response genes such as p53, p21 and GADD45, can be regulated following UV-R 
exposure, and may be important for uveal melanoma development, particularly associated 
with long-term exposure to UV-B. 
•. 
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1.1.1 Uveal Melanoma: Introduction 
• 
Uveal melanoma, the most common primary eye twnour in adults, is derived from 
the melanocytes of the uveal tract, consisting of the iris (3%), ciliary body (5-10%) and 
choroid (-90%). The choroid is the largest part of the uvea and the most common site for 
uveal melanoma (Jager, et al., 2004). Uveal melanoma is characterized by an 
unpredictable clinical course (Woll, et al., 1999), it is often undetectable for months to 
years prior to the occurrence of visual symptoms such as a visual field defect or decreased 
vision related to retinal detachment (Kanski, 1994). 
1.1.2 Uveal Melanoma: Epidemioloa 
The mean incidence of uveal melanoma is 7-8 per million per year [USA- (Seddon, 
et al., 1994); Australia- (V ajdic, et al., 2003)]. Uveal melanoma is usually diagnosed 
between 50 to 75 years of age (Jager, et al., 2004), it is relatively rare in black population, 
and with a slight male-pre.dominance in the non-Hispanic white population (Hu, et al., 
2005). Approximately, 10-40% of patients diagnosed with ·uyeal melanoma will develop 
metastatic disease' within 10 years after treatment of the primary tumour (Woll, et ~., 
1999). M~tastasis is most likely to occur herhatogeneously via the choroid, allowing uveal 
melanoma to develop distant metastases, particulary to the liver (60.5%) and lung (24.4%); 
(Jager, et al., 2004; Rietschel, et al., 2005; Woll, et al., 1999). Development of metastatic 
disease is associated with a mean survival of 2 months for untreated patients and 
approximately 5 months for those who receive treatment after diagnosis (Oragoudas, et al., 
1991). 
1.1.3 Uveal Melanoma: Clinical Features 
'· 
Iris melanomas are easily visible and tend to be detected at an early age. They are 
usually smaller in size than ciliary body and cho~oidal melanomas. Iris melanomas have 
variable pigmentation but they are usually pale in colour (Fig 1.1.1 ). Iris melanomas may· 
adopt a nodular or superficial spreading growth pattern and can be circumscribed or 
diffuse. Malignant iris melanomas often contain prominent and abnormal blood vessels 
visible clinically (Fig 1.1.1) (Hungerford, 1995). 
Figure 1.1.1 
Clinical features of uveal melanoma. 
A. Iris melanoma with prominent blood vessels. • 
B. Iris melanoma viewed by gonioscopy lens and slit-Iamp.2 
C. Ciliary melanoma in a patient's eye.3 
D. Fundus image of a large ciliary body melanoma.4 
E. Fundus image of a large choroidal melanoma with retinal detachment. • 
F. Fundus image of choroidal naevP 
' Image from T he David G.Cogan Ophthalmic Pathology Collection (http://cogancollection.nei.nih.gov) 
11mage from Wake Forest University Baptist Medical centre (wwwl.wfubmc.edu/eye) 
3 lmage from T he Liverpool Ocular Oncology Centre (www.cyetumour.com) 
•tmage from Enriq ue Gareis-Valenzuela eta/ (www.emedicine.com) 
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Ciliary body melanomas are the most diffcult to detect in the early stage due to 
their location (Fig 1.1.1 ). Ciliary body melanomas can be nodular or diffuse, they tend to 
grow circumferentially arotmd the eye, invading the trabecular meshwork and leading to 
glaucoma. They usually become noticeable when the patient suffers pain from glaucoma, 
and visual loss when the tumour grows to invade the choroid, leading to retinal 
detachment. They are associated with a poor prognosis due to their tendency for late 
presentation (Hungerford, 1995). 
Small choroidal melanomas can be detected during routine sight testing whereas 
larger lesions may present with loss of visual acuity caused by the tumour -its~lf, retinal 
detachment or vitreous haemorrhage (Fig 1.1.1 ). Most choroidal melanomas adopt a 
nodular growth pattern and develop a unique mushroom shape when Bruch's membrane 
is ruptured (Fig 1.1.2). Small choroidal melanomas may sometimes be mistaken as 
choroidal naevi (Fig 1.1.1 ). Malignant choroidal melanomas are often associated with a 
thickness of > 1.5mm, serous retinal detachment and the presence of orange lipofuscin 
pigment on the tumour surface (Hungerford, 1995). 
1.1.4 Uveal Melanoma Pathology 
Gross Pathology 
Uveal melanoma can be divided into three groups according to size: small ( <3mm 
height, 5-lOmm diameter), medium (3-5mm height, 10-15mm diameter) and large (>5mm 
height, >15mm diameter) (Shields, et al., 1991). On gross histopathological examination, 
melanomas may be dome or mushroom shaped with a vertical and/or diffuse growth 
pattern (Fig 1.1.2) (McLean, et al., 2004; Shields, et al., 1999). Dome-shaped melanoma 
occurs when the tumour ruptures Bruch' s membrane, herniating through the rupture and 
growing into the subretinal space (McLean, et al., 2004). When the tumour mass in the 
subretinal space is larger than that in the choroid, a mushroom-shaped melanoma is 
formed (McLean, et al., 2004). Inward growth displacing Bruch's membrane (vertical 
growth) is more often seen than lateral growth within the choroid, with no or little 
displacement of Bruch's membrane (diffuse pattern) (COMS, 1998). Retinal detachment 
generally occurs secondary to tumour growth, related to serous exudation from the 
choriocapillaris and the tumour vasculature (Fig 1.1.2). Serous fluid may also track into 
Figure 1.1.2 
Gross pathology of uveal melanoma 
A. Mushroom-shaped melanoma. 1 
B. Diffuse choroidal melanoma.1 
C. Non-pigmented uveal melanoma anterior to the equator.2 
D. Partly pigmented uveal melanoma anterior to the equator.2 
11mages from The David G.Cogan Ophthalmic Pathology Collection 
(http:/ I cogancollection. nei.n ib.gov) 
2Images from Intraocular Tumors (Shields & Shields, 1999) 
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the macula region producing clinical macula oedema. Various stages of photoreceptor 
degeneration, reduction or loss of the outer nuclear layer and outer plexiform layer have 
been. observed associated with retinal detachment secondary to uveal melanoma (Kroll, 
1969). Muller cell hypertrophy and gliosis also ocurred in these cases (Kroll, 1969). 
Similar to cutaneous melanoma, uveal melanoma can be heavily, partially or non-
pigmented (Fig 1.1.2) (Shields, et al., 1999). 
Microscopic Pathology: 
A. Cellular Features 
Uveal melanoma may consist of spindle cells, epithelioid cells or combinations of 
both (mixed cell) (Fig 1.1.3) (Kanski, 1994; McLean, et al., 2004; Shields, et al., 1999). 
Spindle cells are further divided into spindle A or spindle B depending on their nuclear 
features. Spindle A cells contain slender nuclei with fine chromatin, the nucleolus is 
indistinct and the longitudinal infolding of the nuclear membrane often forms a prominent 
basophilic nuclear line Q<anski, 1994; McLean, et al., 2004). Spindle B cells are round or 
oval shape and theii nuclei are plumper than spindle A ~ells, the nucleolus being 
prominent, with poorly differentiated cytoplasmic borders (Kanski, 1994; McLean, et al., 
2004). Epithelioid cells are large oval-shaped melanoma cells with a distinct cell 
membrane, eosinophilic cytoplasm and large round nuclei, which are occasionally 
multinucleated (Kanski, 1994; McLean, et al., 2004). Extracellular spaces often appear 
between adjacent epithelioid cells and this loss of cohesion is an important characteristic 
distinguishing them from spindle qells (McLean, et al., 2004). Their mitotic rate is usually 
greater than spindle cells and they can also vary in size and shape (polymorphism) as well 
as pigmentation (COMS, 1998; Kanski, 1994; McLean, et al., 2004). The most common 
form of uveal melanoma are mixed cell tumours (-50%), followed by spindle cell 
tumours (-30%), then epithelioid cell tumours (COMS, 1998; McLean, et al., 2004)': 
An early morphological study suggested that malignant melanoma may arise from 
pre-existing naevi, and with a relatively flat zone of tumour tissue extending into the 
adjacent uvea, that was usually more pigmented and composed of more mature cells than 
the main portion of the tumour (Y anoff, et al., 1967). These naevi cells were located most 
frequently in the posterior third of the choroid and least frequently in the anterior third of 
. 
Figure 1.1.3 
Cellular features (A & B) and examples of PAS patterns 
(C - F) in uveal melanoma 
A. Spindle cells. (H&E) 
B. Epithelioid cells. (H&E) 
C. Blood vessels (bv). 
D. Parallel channels (arrows). 
E. Arcs/incomplete loops (arrows). 
F. Networks. 
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the choroid and ciliary body (Naumann, et al., 1966). The flat zone located at the base of 
the tumour was later identified as benign-appearing atypical melanocytes (naevus cells), 
and ~ften displayed slender spindle or plump fusiform cells (Y anoff, et al., 1967). 
B. Tumour Microcirculation - V ascu/ature and V ascu/ogenic Mimicry 
The microcirculation in uveal melanomas is complicated and heterogeneous. 
Uveal melanomas are highly vascularised and their vessels often arise from the pre-
existing choroidal vessels (Folberg, et al., 1993). Additionally the cross sections of uveal 
melanoma blood vessels are often irregular with acute angles and concave walls~ possibily 
due to compression by adjacent nests of growing tumour cells (Jager, et al., 2004). 
Tumour vasculature is structurally and functionally different from normal vasculature: the 
vessels are highly disorganized, tortuous and irregular, with excessive branching and 
shunts, possibly due to imbalances of angiogenic regulators such as HIF -1 and VEGF 
(Carmeliet, et al., 2000; Cuenod, et al., 2006). Tumour vessel walls are generally lined by 
fenestrated endothelial cells and an incomplete basement membrane with widened 
interendothelial junctions, and are more permeable than normal capillaries, resulting in 
. . 
extravasation of plasma proteins and erythrocytes to the tumour cells, and facilitating their 
, 
traffic into the bloodstream and subsequent metastases (Carmeliet, et al., 2000; Cuenod, et 
al., 2006; Hashizume, et al., 2000). The microvascular density and microvascular patterns 
(see below) of uveal melanoma have been suggested to be associated with poor prognosis 
but this remains controversial (Al-Jamal, et al., 2003; Chen, et al., 2002; Foss, et al., 1996; 
Lane, et al., 1997; Makitie, et al., 1999). 
Folberg eta/ (1992, 1993) originally observed fibrovascular channels in periodic 
acid-Schiff (PAS) stained uveal melanoma sections and categorized them into nine 
morphological patterns: normal vessels, silent with no vessels, straight with randomly 
distributed vessels, parallel-oriented straight vessels, parallel with cross-linking ve:ssels, 
arcs, arcs with branching, loops and networks (Fig 1.1.3) (Folberg, et al., 1992, 1993). 
Most tumours have areas of more than one o~ these patterns and statistical analysis 
revealed that cross-linked parallel channels, loops and networks were associated with 
poor prognosis (Folberg, et al., 1993, 1997; Makitie, et al., 1999). Initially these PAS 
patterns were believed to be involved in angiogenesis and lined externally by melanoma 
cells but their basal laminar profiles did not resemble blood vessels (Maniotis, et al., 1999; 
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Folberg, et al., 2000). In vitro studies with aggressive uveal melanoma cell lines indicated 
that they were capable of generating cellular channels in the absence of endothelial cells, 
fibrQblasts and soluble growth factors including VEGF (Daniels, et al., 1996). These cell 
lines can also produce type VI collagen, which is believed to contribute to the 
histogenesis of the PAS patterns (Maniatis, et al., 1999). Maniotis et a/ (1999) termed 
these phenomenona "vasulogenic mimcry", describing the formation of vasculogenic-like 
channels by aggressive tumour cells (Maniatis, et al., 1999). These cells express both 
endothelial and epithelial markers, and form channels independent of angiogenesis, that 
lined by tumour cells with a basement membrane (Folberg, et al., 2004). 
The PAS patterns were later reassessed by other researchers who contended that 
they were fibrovascular septa, considered insignificant in terms of uveal melanoma 
prognosis (Foss, et al., 1997; McDonald, et al., 2000). However, several lines of evidence 
suggested that PAS channels were functional and associated with tumour microcirculation. 
First, an active circulating network resembling the PAS patterns were detected in vivo by 
indocyanine green angiography in uveal melanoma patients, suggesting these channels are 
functional (Mueller, et al., 1998). Second, loops and networks are found in hepatic 
metastases and all secondary metastatic sites from ciliary body and choroidal melanomas, 
indicating they are associated with tumour aggressiveness rather than the site of 
dissemination (Folberg, et al., 2000, 2007;·· Rummelt, et al., 1998). Third, electron and 
light microscopy studies confirmed that PAS channels were lined externally by tumour 
cells rather than endothelium (Maniotis, et al., 1999). Finally, a recent study showed that 
uveal melanoma cells synthesized type I collagen, which was also detected in tumour's 
PAS patterns, independent of a host stromal response (Lin, et al., 2005). Functionally, 
vasculogenic mimcry channels have been suggested as a "fluid-conducting network" to 
accommodate the transport of plasma-derived molecules (i.e oxygen and nutrients) into 
the tumour lesion, thereby facilitating tumour growth and progression (Clarijs, et al., 2005; 
Frenkel, et al., 2007). These networks may also be significant for the survival of tumour 
cells, consistent with the observation that necrosis is generally low in uveal melanoma 
(less than 2% with >50% necrosis) and absent in areas that contain PAS patterns with low 
vessel density (Clarijs, et al., 2005; COMS, 1998; Folberg, et al., 2000). 
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Local Spread 
.. Local spread usually occurs transclerally into the orbit but may also invade the 
optic nerve (Kanski, et al., 2005). As the choroid does not possess lymphatic vessels, 
spread to regional lymph nodes is very rare and usually only occurs after the tumour has 
spread extracellularly into the orbit (Jager, et al., 2004; Lindegaard, et al., 2007). 
Distant Spread (Metastases) 
Uveal melanoma is interesting in that it tends to spread purely by haematogenous 
dissemination with a marked tendency to metastasise to the liver (93%), followed by lung 
(24%), bone (16%), skin or subcutaneous tissue (11 %), lymph nodes (10%) and brain (5%) 
(COMS, 2001; McLean, 1993). Multiple metastases are also common (43%) in these 
patients (COMS, 2001). 
1.1.5 Treatments for Uveal Melanoma 
Currently, there are several methods of treatment available for uveal melanoma. 
The choice of appropiate therapy depends on various clinical factors including the size, 
location, extent and apparent activity of the tumor, the general health, age and 
psychological status of the patient, visual acuity of the involved eye as well as the state of 
the fellow eye (Kanski, 1994; Shields, et al., 1999). 
A. Treatment of the Primary Intraocular Tumour 
Laser Therapy 
Photocoagulation using xenon arc or argon laser may be used to treat small to 
medium tumours with signs of growth ( <6.5 disc diameter/ ! Omm widest length and 3mm 
thickness) (Kanski, 1994; Shields, et al., 1999). Photocoagulation is used less frequent 
today as transpupillary thermotherapy (TIT) is now considerd to be more effective 
(Shields, et al., 1999). TIT involves heating the tumour with infrared light and it appears 
to be most effective for small tumours in early stage(< 4mm thickness} (Shields, et al., 
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1999). However TIT may induce vitreous traction on the retina over the choroidal tumour 
and lead to retinal tear or even detachment (Browning, et al., 2003). There are also reports 
showing apparent regression of a choroidal melanoma by TIT, however deeper 
melanoma cells may remain viable resulting in extra-ocular spread (Forte, et al., 2005; 
Godfrey, et al., 1999). Therefore all patients require carefull long term follow-up after 
treatment. 
Radiotherapy 
Radiotherapy using radioactive plaque or charged particles is the mosf common 
treatment modality for medium to large sized melanoma (> 1 Omm diameter) when the 
involved eye has a reasonable chance of retaining some vision (Damato, 2004; Kanski, 
1994; Shields, et al., 1999). COMS has also reported that the survival rate between plaque 
, brachytherapy and enucleation were very similar up to 12 years, hence plaque 
brachytherapy has been increasingly used for medium sized tumours (COMS, 2006; 
Diener-West, et al., 2001). Radioactive plaques contain y- and P-emitting isotopes such as 
!125 and Ru106 are sutured to the sclera over the base of the tumour. This faciliates the 
delivery of a fixed dose of radiation to the tumour while· n_llnimizing damage normal 
tissue (Damato, 2004; Kanski, 1994; Shields, et al., 1999). Side effects of plaque 
brachytherapy and charged particle therapy include radiation retinopathy ( charactersied by 
microaneurysms, haemorrhages, exudates and occasionally retinal neovascularisation), 
which can induce irreversible visual impairment in 42% of patients at 5 years (Cruess, et 
al., 1984; Gunduz, et al., 1999; Kanski, 1994). Other complications. of radiotherapy 
include: cataract, scleral necrosis, hypotony, serous retinal detachment, neovascular 
glaucoma, radiation optic neuropath etc, all of which may compromise vision. More 
recently, proton beam radiotherapy is increasingly being used to treat uveal melanoma 
(Marnitz, et al., 2006). This technique has the advantage of delivering a significant dose 
of radiation to the tumour, while inducing minimal damage to nearby tissue including 
optic disc, lens, ciliary body and retina (particularly the macula), with the potential of 
reducing ocular morbidity (Courdi, et al., 1999). 
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Surgical Resection 
• 
For melanoma located anterior to the ciliary body or in the peripheral choroid, 
partial lamellar sclerouvectomy (known as transcleral resection or TSR) has been used 
where the tumour with a rim of healthy choroid is removed under a scleral flap, without 
disrupting the retina (Kanski, 1994; Shields, et al., 1999). A recent study suggests that 
TSR preserves vision better than plaque brachytherapy but it has a greater risk of local 
recurrence (Puusaari, et al., 2007). 
Recently endoresection of choroidal melanomas has been reported where by a 
posteriorly located tumour is resected via an internal approach. Endoresection following 
irradiation of large uveal melanomas has been shown to be more effective and safer than 
irradiation alone or enucleation (Bechrakis, et al., 2004). 
Enucleation 
Enucleation is generally used for large tumours '(>15mm) especially when the 
involved eye becomes symptomatic and/or blind from complications (Kanski, 1994; 
Shields, et al., 1999). Zimmerman and McLean (1979) (Zimmerman, et al., 1979) 
suggested that enucleation might seed tumour cells systemically promoting tumour 
metastasis and reducing the surivival rate from 85% down to 55% after 15 years based on 
an observation from a hypothetical survival curve. This hypothesis has since been refuted 
by the large COMS trial in the USA which found no difference in survival for medium 
sized tumours for enucleation vs plaque brachytherapy for up to 12 years after treatment 
(COMS, 2006; Diener-West, et al., 2001). 
B. Treatment of Metastatic Disease ·. 
When the tumour has already metastasise.d, treatments may be limited to resection 
of solitary metastases, chemotherapy (hepatic and systemic) and immunotherapy, all of 
which may slightly extend the patient's life (Feldman, et al., 2004; Kanski, 1994). 
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Resection of Solitary Metastases 
• 
Surgical resection of solitary hepatic metastases has been reported to be associated 
with a longer survival rate than other metastatic therapies, but can only be applied for a 
minority of patients with limited metastatic disease to the liver (<10%) (Feldman, et al., 
2004). 
Hepatic Arterial Cltemotherapy 
Hepatic arterial infusion (HAl) involves direct infusion of chemotherapeutic drugs 
into the hepatic artery. HAl is commonly administered by a catheter placed adjacent to the 
hepatic artery via the gastroduodenal artery during laparotomy and connected to a 
subcutaneously implanted pump. The median survival rate for this treatment is around 15 
months and it is limited by its inability to deliver high concentrations of drug to the 
tumour cells without systemic toxicity (Choti, et al., 1999; Feldman, et al., 2004). 
Hepatic artery chemoembolization (HACE) combines hepatic artery· embolization 
with simultaneous infusion of chemotherapeutic drugs (Soulen, 1994). Theoretical this 
treatment allows local embolization in the liver, resulting in necrosis of the tumour area 
with minimum systemic toxicity (Feldman, et al., 2004). However the criteria for using 
HACE are highly selective including that the metastases must only be limited to the liver, 
that the portal venous system is patent so as to tolerate hepatic arterial occlusion, and that 
no biliary obstruction occurs to affect the liver's dependence on arterial flow (Feldman, et 
al., 2004). 
Transarterial chemoembolization (T ACE) in the segmental arteries is another 
approach to chemotherapy for patients diagnosed with early stage liver metastases, and 
has been reported to be well tolerated in 12 patients without any relevant side effects 
(Vogl, et al., 1999, 2006). 
I 
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Systemic Chemotherapy 
• • 
Although numerous studies have attempted to develop systemic chemotherapy for 
disseminated uveal melanoma including fotemustine, gemcitabine plus treosulfan, 
dacarbazine and cisplatin, these agents are associated with many side-effects and have not 
been effective in controlling metastases (O'Neill, et al., 2006; Peters, et al., 2006; Pfohler, 
et al., 2003; Schmittel, et al., 2005). Thus, there is an urgent need for better strategies to 
treat widespread disseminated disease, and further laboratory and therapeutic trials are 
mandatory for the development of such treatments. 
-
Immunotherapy 
Several studies have attempted to introduce immunotherapy as a possible 
treatment for metastatic patients but the results to date are poor. Keilholz et al (1994) 
infused interleukin-2 continuously into the splenic artery, as well &S intravenously infused 
lymphokine-activated killer cells into the hepatic artery or portal vein but found no 
responses. Sato et al. (2002) used hepatic artery immunoe~bolization with granulocyte-
. 
macrophage colony-stimulating factor to stimulate the antigen-presenting cells in 12 
patients with liver metastases, and reported one complete response, four partial responses, 
and stable disease in five patients. 
1.1.6 Prognostic Factors in Uveal Melanoma 
Clinical Factors-Tumour Size 
Uveal melanomas have been classified into three groups based on their height and 
base diameter (Diener-West, et al., 1992). In a meta-analysis on 5-year mortalitY rates 
following enucleation, the mortality rate for small tumours (<3mm in height and <lOmm 
in base diameter) was 16%, medium tumours (3-8mm in height and <15mm in base 
diameter) 32% and large tumours (>8mm in height and >15mm in base diameter) 53% 
(Diener-West, et al., 1992). However it is difficult to use tumour size as a prognostic 
feature when the tumours grow in an irregular shape (McLean, et al., 2004). 
J 
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Clinical Factors-Tumour Location 
• Most of the medium to large tumours have been found to be located either entirely 
or partially posterior to the equator (COMS, 1998). Iris melanoma has the most favorable 
prognosis while ciliary body melanoma has the worst prognosis (Singh, et al., 2001). Iris 
melanoma has the lowest 10-year mortality (3-S%) compared to choroidal and ciliary 
body melanoma. This may be due to iris melanoma being easier to detect in early 
development {Arentsen, et al., 1975; Shields, et al., 2001; Singh, et al., 2001). In a case 
study of3,432 choroidal and ciliary body melanoma, the 15-year mortality was about 46%, 
-
at least 10 times greater than iris melanoma (McLean, et al., 1982; Singh, et al., 2001). 
Histopathological Factors-Cell Type 
Spindle cell tumours have the best prognosis, mixed cell tumours have an 
intermediate prognosis and epithelioid cell tumours have the worst prognosis (Kanski, 
1994; McLean, et al., 1982, 2004). In a study with 3,432 cases of uveal melanoma, the IS-
year mortality of patients with mixed-cell tumours was three times higher ( 60%) than 
patients with spindle ce11 tumors (20%) (McLean, et al., 1982, '20.04). 
Histopathological Factors-Vascular Patterns 
Statistical analysis has indicated that patients with tumours in the absence of loops, 
networks, arcs or parallel with cross-linking vessels have approximately 80% 20-year 
survival rate and tumours with these patterns will reduce down to about 40% (Folberg, e.t 
al., 1993). McLean et al (1997) later simplified the classification into three categories -
presence of loops, presence of equivocal loops and absence of vascular loops, and found 
that the survival rate of patients decreased from 67.5% to 33.8% at 15 years when 
vascular loops were present in the twnours. 
Histopathological Factors- Mitotic Rate 
I 
• 
• 
• 
The prognostic value of the mitotic rate was introduced by McLean et a/ (1977). 
They recommended using 40 HPFs (High Power Fields) to determine the mitotic rate in 
uveal melanoma due to the low number of mitotic figures (McLean, et al., 1977). In a case 
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study with 217 uveal melanomas, tumours with low frequency or mitotic rate (0-1 per 
HPF) were shown to have a better prognosis (15% mortality) compared to tumours with 
high mitotic rate (9-48 per HDF) (56% mortality) in 6 years (McLean, et al., 1977) . 
. 
Consistent with these findings, the mitotic rate was also significantly higher in epithelioid 
cell tumours than in spindle cell and mixed cell tumours (COMS, 1998) 
Immunological Factors 
Several studies have shown that tumour-infiltrating macrophages and lymphocytes 
may be associated with a poor prognosis in uveal melanoma patients (Makitie, efal., 2001; 
Whelchel, et al., 1993). Expression of human leukocyte antigens (HLA class I and II), 
important for immune recognition of tumour cells, has also been associated with uveal 
melanoma metastases and poor prognosis (Ericsson, et al., 2001; Jager, et al., 2004; 
, Krishnaktunar, et al., 2004). This contrasts with other tumours such as cutaneous 
melanoma, breast carcinoma and small cell lung carcinoma where HLA expression is 
associated with better survival (Concha, et al., 1991; Kikuchi, et al., 2007; van Duinen, et 
al., 1988). HLA class I expression may be protective for disseminated melanoma cells by 
• 
blocking natural killer (NK) cell cytolysis, especially in the liver (Blom, et al., 1997; Ma, 
' 
et al., 1995). 
Cytological Factors 
Cytogenetic studies reveal that uveal melanoma is often characterised by clonal 
abnormalities such as loss of material from the long arm of chromosome 1 (lq) (33%), 
monosomy 3 (56%), gain and loss of material in chromosome 6q (78% and 39% 
respectively), trisomy 8 (44o/o) and gain of material in chromosome 8q (78%) (Aalto, et al., 
2001; Dahlenfors, et al., 1993; Horsman, et al., 1993; Hughes, et al., 2005; Kilic, et al., 
2006; Prescher, et al., 1990, 1995; Prescher, et al., 1996; Sandinha, et al., 2004; Scholes, 
et al., 2003; Singh, et al., 1994; Sisley, et al., 1992; Tschentscher, et al., 2000; Wiltshire, 
et al., 1993). Abnormalities in chromosome 3 are found almost exclusively in uveal 
melanoma associated with metastases, and two tumour suppressor genes are proposed to 
correlate with these aberrations (Prescher, et al., 1996; Tschentscher, et al., 2001; White, 
et al., 1998). Gene expression profiling revealed that the presence or absence of 
monosomy 3 defined two distinct uveal melanoma types (Tschentscher, et al., 2003). 
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Furthermore, gene expression profiling has identified two distinct groups of primary uveal 
melanomas - low-grade (group 1) and high-grade (group 2) - where monosomy 3 is 
associated with group 2 (more aggressive) tumours (Onken, et al., 2004). Abnormalities 
of both chromosome 3 and 8 often co-exist in the same tumour and are correlated with 
poor prognosis (Prescher, et al., 1996; Sisley, et al., 1997), whereas an abnormality in 
chromosome 6 may be associated with a better prognosis, even when associated with 
chromosome 3 and 8 aberrations (Baggetto, et al., 2005; Onken, et al., 2004; White, et al., 
1998). The mechanisms underlying the possible protective effect of an abnormality in 
chromsome 6 in uveal melanoma remain to be investigated. 
, _ 
There are several techniques to assess the nonrandom chromosomal abnormalities 
in uveal melanoma including standard cytogenetics with cultured tumour cells (Horsman, 
et al., 1993; Prescher, et al., 1995; Singh, et al., 1994; Sisley, et al., 1990, 1992; 
Tschentscher, et al., 2001), comparative genomic hybridization and microsatellite analysis 
with fresh and paraffin embedded tissue (Aalto, et al., 2001; Hughes, et al., 2005; Scholes, 
et al., 2003; Tschentscher, et al., 2000, 2001), fluorescence in situ hybridization (FISH) 
with fresh tissue and stained slides prepared from tumour cells (Wiltshire, et al., 1993) 
and chromosome in situ hybridization (CISH) with formalin or glutaraldehyde fixed tissue 
(Sandinha, et af, 2004). Recently high-density single nucleotide polymorphism (SNP) 
mapping array with fresh tissue has been shown to be more sensitive in detecting 
chromosome 3 aberrations and monosomy than FISH (Young, et al., 2007). 
1.2 Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases 
mMPs) 
MMPs are a family of enzymes responsible for the degradation of extracellular 
matrix (ECM) constituents including collagen, laminin and proteoglycans. These enzymes 
are important for embryogenesis, wound healing, ECM remodelling as well as 'tumour 
invasion and angiogenesis. MMPs can be secreted, stored or anchored to the membrane 
by a transmembrane domain (membrane-type [MT-] MMPs), and are generally 
subdivided into distinct classes based on their structural differences. MMPs can be 
inhibited by TIMPs, hence their imbalance often results in various pathological processes 
including tumour development and metastases. 
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Molecular Structure of MMPs 
• 
MMPs are synthesized as pro-enzymes and secreted as inactive pro-MMPs in most 
cases. The general structure of MMPs consists of five domain motifs: signal peptide, 
propeptide domain ( ~80 amino acids), metalloproteinase catalytic domain ( ~ 170 amino 
acids), hinge region and a hemopexin domain (-200 amino acids) (Fig 1.2.1) (Nagase, et 
al., 2006; Visse, et al., 2003). 
The propeptide domain has a specific sequence including cysteine- th~~ maintains 
the latency of pro-MMPs by binding zinc ion. The catalytic domain contains a zinc 
binding motif and conserved methionine (Bode, et al., 1992; Dhanaraj, et al., 1996). In 
MMPs, the catalytic domain contains additional zinc and calcium ions for stability and 
expression of enzymatic activity (Nagase, et al., 1999). The C-terminal hemopexin-like 
domain (PEX) is critical for collagenases to cleave collagen, however, the catalytic 
domain is required to maintain proteolytic activity towards other substrates (Bode, 1995; 
Clark, et al., 1989). 
Types of MMPs and TIMPs 
MMPs were originally subdivided into collagenases, gelatinases, stromelysins and 
matrilysins based on their specificity for ECM components. More recently MMPs have 
been observed to share common substrates and can also be grouped according to their 
structural differences (Table 1.2.1, Table 1.2.3, Fig 1.2.1) (Egeblad, et al., 2002; Nagase, 
et al., 2006). There are eight distinct structural classes ofMMPs identified so far: five are 
secreted and three are membrane-type MMPs (Fig 1.2.1) (Egeblad, et al., 2002). 
Collagenases (MMP-1, -8, -13 and -18 in Xenopus) (Table 1.2.1, Table 1.2.3, Fig 
1.2.1) cleave several types of collagens, ECM molecules and soluble proteins (Egeblad, et 
al., 2002; Nagase, et al., 2006; Stamenkovic, 2000). MMP-1 is broadly expressed in 
various normal cells including fibroblasts, macrophages, endothelial cells, epithelial cells 
as well as in tumour cells from colorectal, oesophageal and gastric carcinomas 
(Brinckerhoff, et al., 2000; Inoue, et al., 1999; Murray, et al., 1996, 1998). MMP-1 has 
been reported to be associated with a poor prognosis in colorectal, oesophageal and 
Figure 1.2 Simplified Domain Structure of MMPs 
Minimal-domain MMPs 
MMP-1, -3, -8, -10, -12, -13, -18, -19, -20, -22, -27 
MMP-2,-9 
Furin-activated MMPs 
MMP-11,-28 
Vitronectin-like insert MMPs 
MMP-21 
Transmembrane MMPs 
MMP-14, -15,-16,-24 
GPI-anchored MMPs 
MMP-17, -25 
Type D transmembrane MMPs 
....: ~ . 
MMP-23 
Transmembrane domain !:IIlJ Fibronectin ~ with cytoplasmic tail Signal Peptide type n repeat 
[ ] Propeptide Q Vitronectin-like <I j Propeptide domain with N-insert · terminal signal anchor 
Catalytic domain o ~urin cleavage I > Cysteine array 
with zn++ site 
~ Hinge region ~ MT-Ioop ) > Ig-like domain 
Hemopexin ~ GPianchor domain 
*Adapted from Egeblad and Werb (2002). Nat Rev Cancer, 2(3): 161-74 
Table 1.2.1 Classification of Matrix Metalloproteinases (MMPs) 
Structural class MMP Common name(s) 
Minimal-domain 7 Matrilysin, Matrin, PUMP!, Small uterine metalloproteinase 
... 26 Matrilysin-2, Endometase 
Simple 1 Co llagenase-1, Interstitial collagenase, fibroblast collagenase, Tissue 
hemopexin- collagenase 
domain 
3 Stromelysin-1, Transin-1, Proteoglycanase, Procollagenase-activating 
protein 
8 Collagenase-2, Neutrophil collagenase, PMN collagenase, Granulocyte I 
collagenase 
10 Stromelysin·2~ Transin-2 
12 Metalloelastase Macrophage elastase macrophage metalloelastase 
13 Collagenase-3 
-
18 Collagenase-4 (Xenopus) -
19 RASI-1 
20 Enamelysin 
22 CMMP (Chicken} 
27 None 
Gelatin-binding 2 Gelatinase A, 72-kDa gelatinase, 72-kDa type IV collagenase, neutrophil 
gelatinase 
9 Gelatinase B, 92-kDa gelatinase, 92-kDa type IV gelatinase 
Furin-activa ted 11 Stromelysin-3 
I secreted 
28 Epilysin 
Vitrooectin-Jike 21 .xMMP (Xenopus) ' 
insert 
Transmembrane 14 MTl-MMP MT-MMPI 
15 MT2-MMP, MT-MMP2 
16 MT3-MMP, MT-MMP3 
24 MT5-MMP, MT-MMP5 ! 
GPI-ancbored 17 MT4-MMP, MT-MMP4 
25 MT6-MMP, MT-MMP6, Leukolysin 
Type II 23 Cysteine array MMP (CA-MMP), Femalysin, MIFR 
~ral!~tll~mbrane 
"'Adapted from Egeblad and Werb (200~). Nat Rev Cancer 2(3): 161-74. 
Table 1.2.2 Properties of Tissue Inhibitors of Metalloproteinases (TIMPs) 
TIMP-1 TIMP-2 TIMP-3 TIMP-4 
Expression inducible mainly constitutive inducible unknown 
Main form diffusible secreted diffusible secreted ECM-associated diffusible 
secreted 
MMP-2 No Yes No No 
I 
activation 
MMPs MMP-1,-2,-3,-7,·8, MMP-1, -2, -3,-7, -8, -9, MMP-1,·2,-3,-9, - MMP-1, -2, -3, ~ 
inhibited -9, -10,-11,-12,-13, -1 0,-13,-14,-16, -17, - 13,-14. -16,-17, - 8, -9, -14, -19 
-17, -19,-25,-26, 19, -24, -25, -26 19, -25, -26 
*Adapted from Egeblad and Werb (2002). Nat Rev Cancer 2(3): 161-74. 
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gastric cancers (Inoue, et al., 1999; Murray, et al., 1996, 1998), although high expression 
of MMP-1 in human metastastic cutaneous melanoma cells has been reported to be 
cGITelated with a favourable treatment response (Nikkola, et al., 2001). A recent study 
suggested that MMP-1 activated protease activated receptor 1 (PAR-I) and promoted 
growth and invasion of breast carcinoma cells (Boire, et al., 2005). Cleavage products of 
MMP-1, -8 and -13 can be rapidly denatured to gelatin and further degraded by 
gelatinases (MMP-2 and -9) (Stamenkovic, 2000). MMP-8 has been reported to be 
expressed in neural crest cells during early development as well as in cutaneous 
melanoma cells (Giambemardi, et al., 2001). 
,, 
Gelatinases (MMP-2 and -9) (Table 1.2.1, Table 1.2.3, Fig 1.2.1) preferentially 
degrade collagens but they can also digest laminins (Egeblad, et al., 2002; Nagase, et al., 
2006; Stamenkovic, 2000). Increased MMP-2 expression has been detected in various 
human cancers including carcinoma of the colon, pancreas, prostate, bladder, skin, breast 
and ovary (Yu, et al., 1996). Activated MMP-2 is strongly associated with tumour cell 
invasion and metastasis in several human cancers including colorectal, pancreatic and 
cervical cancers (Koshiba, et al., 1997; Sheu, et al., 2003; Waas, et al., 2002; Yu, et al., 
1996). Furthermo.re MMP-2 is also proposed as a prognostic marker of uveal melanoma 
(see next section) (Vaisanen, et al., 1999). MMP-9 expression is often low or absent in 
normal tissue, however, it can be induced in wound healing and tumour invasion (Egeblad, 
et al., 2002; Stamenkovic, 2000). 
Stromelysins (MMP-3, -10 and -11) (Table 1.2.1, Table 1.2.J, Fig 1.2.1) are 
predominantly expressed by normal epithelium but can also be found in carcinomas 
(Stamenkovic, 2000). MMP-3 is involved in mammary epithelial cell apoptosis and 
alveolar formation (Nagase, et al., 2006). MMP-11 was originally identified in the stromal 
cells surrounding invasive breast carcinomas and it cleaves IGFBP, a2-macroglobulin and 
a1-proteinase inhibitor (Table 1.2.2) (Basset, et al., 1990; Egeblad, et al., 2002). A1though 
MMP-12 (macrophage metalloelastase) doesn't belong to stromelysin subgroup, it is 
structurally similar to MMP-3 and -~0 (Fig .1.2.1) (Egeblad, et al., 2002). MMP-28 
(epilysin) shares a common structural class with MMP-11 and it is broadly expressed in 
both normal and fetal tissue (Fig 1.2.1) (Egeblad, et al., 2002; Lohi, et al., 2000; 
Marchenko, et al., 2001). MMP-28 has been observed in several carcinomas including 
Table 1.2.3 Matrix Metalloproteinases (MMPs) and their 
substrates 
.MMP Substrate(s) 
1 ·collagens (type I-III, VII, Vlli, X, XI), gelatins, aggrecan, brevican, entactin/nidogen, 
fibronectin, IGFBP, laminin, link protein, myelin basic protein, tenascin, vitronectin, al-
antichymotrypsin, a2-macroglobulin, a)-proteinase inhibitor, C1q, casein, CXCL12, fibrin, 
fibrinogen, IL-113, L-selectin, pro-TNF-a, pro-MMP-2, -9 
2 Collagens (type I, III-V, VII, X, XI), gelatins, aggrecan, brevican, decorin, elastin, 
entactin/nidogen, fibrillin, fibronectin, fibulins, IGFBP, laminin, link protein, myelin basic 
protein, osteonectin, tenascin, vitronectin, al-antichymotrypsin, at-proteinase inhibitor, 
ADAMTS-1, C1q, CCL7, CXCL12, endothelin, FGFRI, fibrin, fibrinogen.t ~alectin-3, IL-113, 
pro-MMP-9, MMP-13, plasminogen, substance P, latent TGFf3, pro-TNFa 
3 Collagens (type III-V, VII, IX-XI), gelatins, aggrecan, brevi can, decorin, elastin, 
entactin/nidogen, fibrillin, fibronectin, IGFP, link protein, myelin basic protein, osteonectin, 
osteopontin, perlecan, tenascin, vitronectin, al-antichymotrypsin, a2-macroglobulin, al-
proteinase inhibitor, Clq, casein, CXCL12, E-cadherin, fibrin, fibrinogen, pro-HB-EGF, IL-113, 
L-selectin, pro-MMP-1 , -7, -8, -9, -13, NCI fragment of collagen XVIII, PAI-l, plasminogen, 
substance P, T kininogen, pro-TNF-a, uP A 
7 Collagens (type I, IV), gelatins, aggrecan, brevican, decorin, elastin, entactin/nidogen, 
fibronectin, flbulins, laminin, link protein, myel~ basic protein, osteonectin, osteopontin, 
te~~cin, vitronectin, al -proteinase inhibitor, casein,"E~adherin, FAS ligand, fibrinogen, pro-
HB-EGF, 134 integrin, pro-MMP-1, -2, -9, plasminogen, pro-TNF-a 
8 Collagens (type 1-lii), aggrecan, brevican, a2-macroglobulin. a !-proteinase inhibitor. 
ADAMTS-1 . Clq, fibrinogen, substance P 
9 Collagens (type IV, V, XI, XIV), gelatins, aggrecan, decorin, elastin, fibrillin, IGFBP3, laminin, 
link protein, myelin basic protein, osteonectin, vitronectin, cx2-macroglobulin, at -proteinase 
inhibitor, casein, Clq, CXCLl, CXCL4, CXCL7-precursor, CXCL12, endothelin, fibrin, 
fibrinogen, galectin-3 ,.IL-lf3, IL-8/CXCL8, IL-2Rcx, c-kit ligand, pro-MMP-2, NCl fragment of 
collagen XVIII, plasminogen, substance P, latent TGF-!3, pro-TNF-cx 
10 Collagens (type lli-V), gehitins, aggrecan, brevican, elastin, fibronectin, link protein, casein, 
fibrinogen, pro-MMP-1, -7, -8, -9 
11 IGFBP. a2-macroglobulin, at-proteinase inhibitor 
12 Collagens (type I, IV), gelatins, aggrecan, elastin, entactin/nidogen, fibrillin, fibronectin, 
laminin, myelin basic protein, vitronectin, a2-macroglobulin, at-proteinase inhibitor, factor 
XII, fibrinogen, lgG, NC 1 fragment of collagen XVIII, plasminogen, pro-TNF·a 
13 Collagens (type I-IV, VI, IX, X, XIV), gelatins, aggrecan, brevican, fibrillin, fibronectin, 
osteonectin, tenascin, cx2-macroglobulin, Clq, casein, CXCL12, factor XII, fibrinogen, pro-
MMP-9, NCI fragment of collagen XVIII 
L_ 
--- - - --- - -
Table 1.2.3 Matrix Metalloproteinases (MMPs) and their 
substrates (cont.) I ~ 
MMP Substrate(s) 
14 Collagens (type I·III), gelatins, aggrecan, entactinlnidogen, fibrillin, fibronectin, perlecan, I 
vitronectin, a.2·macroglobulin, al·proteinase inhibitor, CD44, CXCL12, factor XII, fibrin, 
fibrinogen, av integrin, pro·MMP·2, ·13, tenascin, tissue transglutaminase, pro·TNF·a I 
15 Aggrecan, entactin/nidogen, fibronectin, laminin, perlecan, tenascin, tissue transglutaminase, 
ADAMTS-1, pro-MMP-2 I 
16 Collagen III, gelatin, casein, fibronectin, tissue transglutaminase, pro-MMP-2 
17 Gelatin, fibrin, fibrinogen, pro-MMP·2, pro·TNF-a --- I 
-
18 Collagen I, gelatins 
I 
19 Collagen (type I, IV), gelatins, aggrecan, cartilage oligomeric matrix protein, entactinlnidogen, 
fibronectin, laminin, tenascin, casein 
20 Aggrecan, amelogenin, cartilage oligomeric matrix protein, NCl fragment of collagen XVIII I 
. 
21 Unknown 
22 Casein gelatin 
23 Unknown I 
24 Gelatin, fibronectin, pro-MMP-2 I 
25 Collagen type IV, gelatin, fibronectin, fibrinogen, fibrin pro-MMP-2 
26 Collagen type IV, gelatin, fibronectin, fibrinogen, fi~rin, vitronectin, at-proteinase inhibitor, 1 
casein, pro·MMP-9 
27 Unknown 
28 Casein 
*Adapted from Egeblad and Werb (2002). Nat Rev Cancer 2(3): 161-74. 
·. 
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colon adenocarcinoma, ovarian carcinoma and pancreatic adenocarcinoma (Marchenko, et 
al., 2001). 
Matrilysins (MMP-7 and MMP-26) lack of hemopexin domain and structurally 
classified as minimal-domain MMPs (Table 1.2.1, Table 1.2.3, Fig 1.2.1) (Egeblad, et al., 
2002; Nagase, et al., 2006). MMP-7 is mainly stored in secretory epithelial cells of 
various organs including endometrium, small intestine, breast, pancreas, liver and prostate, 
as well as tumours including prostate and breast carcinoma (Nagase, et al., 2006; 
Saarialho-Kere, et al., 1995). MMP-26 is found in the placenta, epithelial conjunctiva 
-
cells of the human eye, endometrioid tumours, epithelial tumours and breast-cacinoma, 
suggesting its involvement in normal development and pathology (de Coignac, et al., 
2000; Marchenko, et al., 2001, 2004). MMP-26 can cleave fibrinogen in a manner similar 
to MTI-MMP, and may also participate in angiogenesis involving fibrin formation and 
degradation (Hiraoka, et al., 199.8; Marchenko, et al., 2001). Unlike other MMPs, MMP-
26 is mainly stored intracellularly (Marchenko, et al., 2004). 
MMP-19 is one of the recently discovered MMP members and structurally 
. . 
belongs to simple.hemopexin-domain MMPs (Egeblad, et ·al., 2002; Pendas, et al., 1997) 
. . 
(Table 1.2.1, Table 1.2.3, Fig 1.2.1 ). MMP-19 cleaves various ECM components as well 
as cartilage oligomeric matrix protein (COMP), which found in cartilage and tendons 
(Table 1.2.2) (Stracke, et al., 2000). MMP-19 is expressed in macrophages, smooth 
muscle cells and keratinocytes, and MMP-19 mRNA is also upregulated in psoriatic 
keratinocytes and skin (Suomela, et al., 2003). MMP-19 was strongly expressed in the 
synovial capillary endothelial ~Us found in an acutely inflamed tissue, suggesting its 
involvement during acute inflammation and angiogenesis (Kolb, et al., 1999). 
Downregulation of MMP-19 in tumour cells and vessels has been reported to be 
associated with increased breast tumour invasiveness, suggesting that MMP-19 might 
inhibit malignant transformation, unlike other MMPs (Djonov, et al., 2001). 
Apart from secreted MMPs, there are six. cell membrane-associated MMPs that are 
categorized as membrane-type MMPs (MT-MMPs). MT-MMPs can be further divided 
into two subgroups, the transmemebrane and the glycosylphosphatidyl inositol (GPI)-
anchored MT-MMPs (Egeblad, et al., 2002; Nagase, et al., 2006). MT1-, 2-, 3-, and 5-
MMPs belong to the transmembrane MT -MMPs, and contain a transmembrane and 
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cytoplasmic tail domain, while MT4- and MT6-MMP belong to GPI-anchored MT-MMPs 
and possess a GPI anchor instead of a transmembrane and cytoplasmic tail domain (Table 
1.2.: I, Table 1.2.3, Fig 1.2.1) (Egeblad, et al., 2002; Handsley, et al., 2005; Kojima, et al., 
• 
2000; Nagase, et al., 2006; Pei, 1999; Stamenkovic, 2000). 
MTl-MMP (MMP-14) degrades various substrates including type I collagen, 
fibronectin, laminin, fibrin and gelatin (Table 1.2.1, Table 1.2.3). MTl-MMP is important 
in angiogenesis as it allows endothelial cells to retain the surrounding matrix for structural 
support by restricting their proteolytic activity to the pericellular milieu (Hiraoka, et al., 
1998; Nguyen, et al., 2000). MT2-MMP (MMP-15) preferentially degrades-fibronectin, 
laminin and tenascin (Table 1.2.2). Both MTl- and MT2-MMP can activate pro-MMP-13 
(Stamenkovic, 2000). MT3-MMP (MMP-16) commonly degrades type III collagen, 
gelatin and fibronectin (Table 1.2.2) (Egeblad, et al., 2002; Stamenkovic, 2000). MT4-
(M!v1P-17), MT5- (MMP-24) and MT6-MMP (MMP-25) are the most recently discovered 
MT-MMPs. In contrast to other MT-MMPs, MT5-MMP can act as both a cell bound and 
soluble proteinase for ECM degradation (Pei, 1999) . 
.. 
MTl- and .Mt3-MMP expression has been obse~ed in fibroblasts, macrophages 
. ' 
and osteoclast-like cells at bone resorption sites in rhewnatoid arthritis, suggested they 
might be responsible to the matrix degradation during rheumatoid arthritis development 
' (Pap, et al., 2000). Northern blot analysis has demonstrated MT5-MMP predominantly 
expressed in the brain, kidney, pancreas and lung (Llano, et al., 1999). In particular, MT5-
MMP has been found to be expressed in the cerebellum and may be involved in neuronal 
• 
development as well as in regulating axonal growth (Hayashita-Kinoh, et al., 2001; 
Jaworski, 2000; Pei, 1999; Sekine-Aizawa, et al., 2001). MT5-MMP is also detected at 
high levels in brain tumours such as astrocytomas, compared to normal brain tissue (Llano, 
et al., 1999). MT6-MMP is predominantly expressed in leukocytes, lung and spleen, and 
is detected at high levels in colon carcinoma and some astrocytomas and glioblastomas; 
MT6-MMP is not detected in normal colon or brain tissue (Pei, 1999; Velasco, et al., 
2000). All MT-MMPs (except MT4-MMP) can activate pro-MMP-2, which may also 
' 
facilitate tumour progression (Llano, et al., 1999; Pei, 1999; Nagase, et al., 2006; 
Stamenkovic, 2000; Velasco, et al., 2000). 
' 
Factors 111Volved in the Pathogenesis of Human Uveal Melanoma 19 
TIMPs are physiological MMP inhibit.ors, and to date four different structurally 
related members (TIMP-1 to -4) have been identified (Table 1.2.2) (Lambert, et al., 2004; 
Nagase, et al., 2006). Structurally TIMPs consist of N- and C- terminal domains, each 
containing six conserved cysteine residues forming three disulfide bonds and the N-
terminal folds as an independent unit during the inhibitory activity (Nagase, et al., 2006; 
Williamson, et al., 1990). The N-termina) domain provides sufficient MMP inhibition, 
while the C-terminal domain is important for protein-protein interactions and regulates 
MMP activation by binding to pro-MMPs (Lambert, et al., 2004). 
TIMP-1 is expressed in numerous cultured cell types including fibroblasts; smooth 
muscle celJs, osteoblasts, chondrocytes, epithelial and endothelial cells (Lambert, et al., 
2004). In pathology, TIMP-1 associated with poor prognosis in various human cancers 
including metastatic breast cancer, colorectal cancer, lung carcinoma and lymphoma 
(Chirco, et al., 2006). 
TIMP-2 inhibits MMP-2 and MTl-MMP but at low concentration it forms a tri-
molecular complex with MT1-MMP and proMMP-2, mediating activation ofproMMP-2 
(Goldberg, et al., 1992; Gomez, et al., 1997; Ward, et al., 1991). 
TIMP-3 is a unique member of the TIMP family in that it is water insoluble and 
bound tightly in the ECM, mainly by heparan sulphate proteoglycans (Yu, et al., 2000). 
TIMP-3 was first identified in chicken embryo fibroblasts and referred to as ChiMP-3, 
however sequence analysis revealed that this protein was similar to other TIMPs and it 
was subsequently renamed TIMP-3 (Pavloff, et al., 1992). TIMP-3 is the only TIMP that 
inhibits ADAMs (a disintegrin and metalJoproteinase) family members such as tumour 
necrosis factor a-converting enzyme, which may account for its ability to induce tumour 
celJ apoptosis (Ahonen, et al., 1998; Smith, et al., 1997). Furthermore TIMP-3 is also the 
only TIMP to inhibit shedding of interleukin-6 receptors and L-selectin (Borland, 'et al., 
1999; Hargreaves, et al., 1998). 
TIMP-4 is structurally similar to TIMP-2, and also inhibits MMP-2 and MTl-
- MMP, but does not directly promote MMP-2 activation (Hemandez-Barrantes, et al. , 
2001). TIMP-4 inhibits capillary endothelial cell migration but it does not inhibit 
proliferation and angiogenesis in vivo (Fernandez, et al., 2006). 
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Besides inhibiting MMPs, TIMPs are also involved in other biological processes 
including promotion and inhibition of cell growth and angiogenesis, apoptosis and 
embryogenic implantation (Lambert, et al., 2004). TIMP-1 and -2 induce cell growth in a 
wide range of cells including keratinocytes, fibroblasts and osteosarcoma cells, while 
TIMP-3 has been reported to induce cell growth in non-transformed chicken embryonic 
fibroblasts (Lambert, et al., 2004). Interestingly, TIMP-2 and -3 have also been reported to 
inhibit cell growth in cultured endothelial cells, several human carcinoma cell lines and in 
a neuroblastoma mouse model (Bian, et al., 1996; Miyake, et al., 1999; Murphy, et al., 
1993; Spurbeck, et al., 2003). As mentioned above, TIMP-2 can activate pro-MMP-2 with 
MT1-MMP and promote angiogenesis; in contrast, overexpression of 'FIMP-1 in 
pancreatic cancer cell lines resulted in angiogenesis inhibition and TIMP-3 was also 
reported to inhibit angiogenesis in neuroblastoma mouse model (Bloomston, et al., 2002; 
Goldberg, et al., 1992; Gomez, et al., 1997; Spurbeck, et al. , 2003; Ward, et al., 1991). 
TIMP-1 and -2 were associated with anti-apoptotic activity in several cell lines whereas 
TIMP-3 promoted apoptosis in smooth muscle cells (Lambert, et al., 2004). Furthermore 
TIMP-1 and -3 were up-regulated during mouse embryo implantation (Alexander, et al., 
1996). 
MMP and TIMPs in Uveal Melanoma Growth & Invasion 
As discussed above MMPs and TIMPs are involved in many human cancers and 
several studies have investigated their role in uveal melanomas. MMP-2 has been 
proposed as a prognostic marker of uveal melanoma (Vaisanen, , et al., 1999). 
Immunoreactivity for MMP-2 h~ also been observed in RPE, corneal epithelium, 
fibroblasts in the ciliary body and choroid of melanoma eyes (Vaisanen, et al., 1999). 
MMP-9 has also been found to be expressed in uveal melanomas, predominantly in 
epithelioid melanomas or the epithelioid portion of mixed-cell melanomas (El-Shabrawi, 
et al., 2001; Sahin, et al., 2007). Both MMP-2 and -9 have been associated with a high 
incidence of metastatic disease in uveal melanoma; tumours expressing the M~P 
inhibitors, TIMP-1 & -2, were however correlated with a better patient survival rate (El-
Shabrawi, et al., 2001; Elshaw, et al., 2001; Vaisanen, et al., 1999). A preliminary study 
has shown that uveal melanomas with mixed morphology expressed MMP-2, -9, -13 and 
MT1-MMP (Laver, 2002). Prinomastat, a selective inhibitor of MMP-2, -9, -13 and -14, 
has been shown to induce apoptosis and necrosis in a rabbit model of uveal melanoma 
I 
~ 
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rabbit, further suggesting a role for MMPs in tumour growth (Ozerdem, et al., 2002). An 
in-vitro study of 15 primary uveal melanoma cell lines found that all secreted pro-MMP-2, 
with nine secreting pro-MMP-9 (Cottam, et al., 1992). TIMP-3 has been recently 
suggested to be involved in the development of uveal melanoma with a 5-fold decrease in 
expression in a metastatic uveal melanoma cell line (van der Velden, et al., 2003). As 
mentioned previously, angiogenesis and vasculogenic mimicry are critical in the 
development and metastases of uveal melanomas (Folberg, et al., 2000). MMPs and 
TIMPs have complex regulatory activities in angiogenesis, including degradation of 
basement membrane, capillary tube formation, endothelial cell proliferation and migration 
(Kumar, et al., 1998). Active MMP-2 and MTl-MMP have been rep(>ned .to cleave 
Laminin 5y2 chain to produce y2 • and y2X fragments, which are necessary for 
vasculogenic mimicry in aggressive uveal melanoma (Se:ftor, et al., 2001). 
1.3 Adhesion Molecules in Uveal Melanoma Growth and Invasion 
Adhesion molecules play an important role in the growth and invasiveness of 
tumour, and may also contribute to hematogenous tumour dissemination. Tumour cell 
adhesion_ molec~~es C'an promote cell binding to vascular. en~othelium, which associated 
with increased MMP secretion, may be important for allowing tumour cells to enter blood 
vessels and spread throughput the body. 
Uveal melanomas express a variety of adhesion molecules including members of 
the immunoglobulin (Ig) superfamily and integrins (Anastassiou, et al., 2000a, 2000b; 
Beliveau, et al., 2000; Elshaw, et al., 2001; Pardo, et al., 2005; Seftor, et al., 1999). In 
uveal melanoma, for example, intercellular cell adhesion molecule-1 (ICAM-1) has been 
reported to be strongly expressed in uveal melanomas and correlated with large tumour 
size (>2000mm3) (Lawry, et al., 1999). Other immunohistochemical studies have also 
found that uveal melanoma strongly expresses ICAM-1 80% of tumours - (Anastassiou, 
et al., 2000b). This study reported decreased ICAM-1 expression associated with an 
increased risk of metastasis within the first 5 years after diagnosis (Anastassiou, et al., 
2000b). Further support for involvement of ICAM-1 in uveal melanoma spread comes 
from a recent study, that showed that an anti-human ICAM-1 antibody could inhibit the 
spread of human uveal melanoma cells injected into the anterior chamber or 
subcutaneously, in a SCID mice mouse model (Wang, et al., 2006). 
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Sections of primary uveal melanomas with vascular networks have been observed 
to strongly express integrin VLA~2, whereas loss of VLA~3 and av was associated with 
scleral infiltra~on and extraocular growth of the tumour (Anastassiou, et al., 2000a). 
Another study found that compared to a non~invasive cell line, an invasive uveal 
melanoma cell line expressed al and a4 integrin, with higher levels of a1~3, a5 and 6 
integrin subunits (Woodward, et al., 2005). In vitro studies also showed that membrane~ 
bound integrin, a5~1, was not detectable in epithelioid cell lines, while low levels of 
a5~ 1 were found in primary cultured melanocytes, spindle and mixed uveal melanoma 
cell lines, suggesting that loss of a5~1 might be related to growth of ep!!_helioid uveal 
--
melanomas (Beliveau, et al., 2000). Higher levels of a5~3 expression were detected in 
spindle compared with epithelioid cell lines, suggesting that changes in this integrin may 
lead to metastases (Seftor, et al., 1999). Spindle cell melanomas and melanocytes were 
also reported to lack the laminin~binding integrin, a6~1, hence it may be a possible 
prognostic marker of uveal melanoma (Elshaw, et al., 2001). 
The Role of CD 146 (Melanoma Cell Adhesion Molecule) in Tumour Development and 
Metastases 
Another member of the lg superfamily, CD146, was originally identified as a 
cutaneous melanoma specific protein, and has recently been discovered to be associated 
with the invasiveness of several uveal melanoma cell lines (Pardo, et al., 2005). CD146 is 
a cell surface adhesion molecule, previously designated by different names, including 
MUC18 (Mucin isotype 18), A32 antigen, MCAM, Mel~CAM (melanoma cell adhesion 
molecule) and S~endo~1, due to its identification in different tissues by several 
independent research groups (Shih, 1999). The name Mel~CAM or MCAM originally 
reflected the functional aspect of CD 146, since it was shown to be a cell adhesion 
molecule in cutaneous melanoma cells (Shih, 1999). 
Molecular Structure ofCD146 
CD146 is a highly glycosylated, 113 kDa single chain molecule (Shih, et al., 1994). 
CD146 contains a V~V~C2~C2~C2 immunoglobulin~like unit in the extracellular domain, 
an amino acid stretch (LKEEKN) and a relatively short cytoplasmic tail with several 
NH2 
CD 146 
p59fyn 
p125FAK 
paxillin 
Cell membrane 
\ 
Figure 1.3 
Molecular structure of CD 146 
*Adapted from Shih (1999). J Pathol, 189: 4-11. 
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phosphorylation sites (Seftalioglu, et al., 2000; Shih, 1999) (Fig. 1.3). Activation in the 
cytoplasmic domain of CD 146 associates with p59fyn, a Src family kinase known to 
phosphorylate p125FAK and leads to its association with paxillin, a cytoskeletal protein 
essential in focal adhesion assembly (Anfosso, et al., 1998) (Fig. 1.3). 
Functions of CD 146 
CD 146 is involved in numerous biological processes including cell adhesion and 
migration, vascular development and embryo implantation (Liu, et al., 2004; Shih, et al., 
- ~ 
1997). CD146 is expressed in vascular endothelium, activated T-lymphocytes, 
myofibroblasts, smooth muscle, Schwann cells and retinal ganglion cells (Bardin, et al., 
1996; Shih, et al., 1998). It has also been proposed as a marker of angiogenic vascular 
endothelium (St Croix, et al., 2000; Yan, et al., 2003). Confocal and electron microscopic 
analysis of confluent human umbilical vein endothelial cells suggested that CD146 is a 
structural component of the endothelial junctions (Bardin, et al., 2001). Although CD146 
has been suggested as a mediator of cell-cell interactions, its heterophilic ligand and 
mechanism of binding are still unidentified (Bardin, et al., 2001; Shih, et al., 1997). 
CDJ46 in Tumour Development 
CD 146 is involved in the growth of various tumours including cutaneous 
melanoma, breast and prostate cancer (Sers, et al., 1994; Shih, et al., 1997; Wu, et al., 
2001). CD146 expression is strongly up-regulated in malignant cutaneous. melanoma cells 
compared to benign nevi, particularly in metastatic lesions (Johnson, 1994; Lehmann, et 
aJ., 1987, 1989; Wu, et al., 2001). In tissue microarrays of cutaneous melanomas, CD146 
immunostaining is reported to be a highly significant independent prognostic marker 
inversely correlated with survival of melanoma patients (Pacifico, et aJ., 2005). CD146 
expression in cutaneous melanoma cells increased tumour growth and metastases, while 
decreased expression reduced cell tumourigenicity, further supporting its role in 
promoting cutaneous melanoma progression (Satyamoorthy, et al., 2001; Xie, et aJ ., 1997). 
Furthermore both in vitro and in vivo studies in cutaneous melanoma indicate that CD 146 
- antibody can target both CD 146-positive melanoma cells and tumor vascular endothelium, 
with possible inhibitory therapeutic effects on cutaneous melanoma growth and 
metastases (Leslie, et aJ., 2007; McGary, et al., 2003; Melnikova, et al., 2006). CD146 
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protein has been recently discovered to be associated with invasiveness of some uveal 
melanoma cell lines (Pardo, et al., 2005). The distribution and expression of CD 146 in 
primary uveal melanoma remains to be been established. The expression of CD 146 in 
primary uveal melanoma and its association with tumour growth is further explored in 
Chapter4. 
1.4 Risk Factors in Uveal Melanoma: Involvement of Ultraviolet (lJV) Radiation 
Epidemiological studies indicate that risk factors associated with increased 
-
incidence of uveal melanoma include age, occupation (in particular welding), race, iris 
colour, exposure to sunlamp radiation and cumulative exposure to ultraviolet (UV) 
radiation, particularly up to the second decade of life (Holly, et al., 1990; Hu, et al., 2005; 
Li, et al., 2000; Tucker, et al., 1985; Vajdic, et al ., 2001, 2002, 2004). The relationship 
between cutaneous melanoma and lN exposure in particular, suggests that there may be a 
role for lN in uveal melanoma. 
UV Exposure to the Human Eye 
Solar radiation that passes through the earth's atmosphere consists of the visible 
spectrum (400-700 nm) and UV radiation (200-400 nm). UV can be divided into three 
groups, namely UV-A (315-400 nm), UV-B (290-315 nm) and UV-C (200-290 nm). 
When the human eye is exposed to sunlight its anterior portion absorbs most of the 
UV, leaving approximately 1% UV reaching the retina (Sliney, 2002) (Fig 1.4.1). The 
cornea absorbs most of the UV-A and UV-B, and this absorption increases with age 
(Lerman, 1980). In early childhood the lens absorbs approximately 25% UV, and this 
increases up to 80% by the age of 80 years (Lerman, 1980). Finally, about 30% of the 
remaining UV will be further absorbed by the retinal pigmented epithelium (RPE) before 
it reaches the choroid (Peyman, et al., 1984). Although the choroid and ciliary body are 
well protected from lN in adults, substantial transmission of UV-A and UV-B is received 
in early childhood, and decreases slowly with age (Holly, et al., 1990; Seddon, et al., 
1990). 
nm QJ Absorption (0/ 0 ) 
<280 • • ••• ....1.0 
UV-BI 300• J •••• ~2 •• 45 I 320 • • ••• I • • • • • n 
37 \ 
UV-AI 340 J ••• 1: •• 
360 •••••• ~4 •• I: 
Figure 1.4 
I 
\ 
,.--Cornea 
If) 
14 
-Aqueous 
Lens 
I 36 I 
I 14 I 
Relative absorption of visible UV radiation within a human eye 
*Adapted from Sliney (2002). lnt J Toxicol, 21(6): 501-9 
Vitreous 
r----Retina 
1 
1 
Factors Involved in the Pathogenesis of Human Uveal Melanoma 25 
UV Exposure: a Risk Factor in Uveal Melanoma? 
· The Aus~alian environment is known to receive high levels of UV related to its 
geographical location, and the Australian population is reported to have the highest 
incidence of cutaneous melanoma in the world (Gies, 2003). Cutaneous melanoma is 
believed to be derived from cutaneous melanocytes. Both cutaneous and choroidal 
melanocytes are known to originate from melanoblasts that migrate from the neural crest 
during embryogenesis (Nordlund, 1989). Differentiated melanocytes in each tissue bed are 
identical hence it has been proposed that risk factors important in the development of 
cutaneous melanoma, such as UV exposure, may also be significant in uveal melanoma 
(Hurst, et al., 2003). 
Numerous studies have investigated whether UV exposure is a potential risk factor 
m the development of uveal melanoma and this remains controversial. Several 
epidemiological studies have indicated that UV exposure was not a significant factor in 
the development of uveal melanoma (Pane, et al., 2000; Schwartz, et al., 1997; Seddon, et 
al., 1990; Shah, et al., 2005) and reported no clear association between lifetime 
accumulative UV-B. ~xposure, outdoor activities and develop~ent of uveal melanoma 
(Pane, et al., 2000; Seddon, et al., 1990). Pane et al (2000) assumed that UV-B might 
contribute to conjunctival melanoma rather than uveal melanoma due to the anterior 
portion of the eye receiving more UV than the choroid (Pane, et al., 2000). Schwartz et al 
(1997) have also pointed out that if UV is responsible for the development of uveal 
melanoma then its incidence should be influenced by geographical location similar to 
cutaneous melanoma, but no such r~lationship has been found (Schwartz, et al., 1997). 
However, other epidemiological studies support a role for UV exposure as a 
potential risk factor in the development of uveal melanoma. (Holly, et al., 1990; Tucker, 
et al., 1985; Vajdic, et al., 2002). In partic\}}.ar, an Australian study indicated that" sun 
exposure during the first 20 years of age, as well as outdoor occupations or activities in 
men before 30 years of age, were the most important risk factors associated with uveal 
melanoma (Vajdic, et al., 2002). This observation is consistent with the fact that a 
substantial amount of choroidal exposure to UV occurs during childhood to adolescence 
when the lens is still transparent (see above) (Holly, et al., 1990; Seddon, et al., 1990). 
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1.5 Aims 
As discussed in ~is Chapter, growth and development of uveal melanoma involves both 
cellular and environmental factors. To further investigate these factors, this thesis aimed 
to: 
1. Describe the expression and distribution of MMP-9 and TIMP-3 in primary uveal 
melanoma tumours and normal human eyes (Chapter 3). 
2. Examine the in vitro expression of melanoma cell adhesion molecule (CD146fin a 
series of uveal and metastasis-derived cell lines and primary uveal melanocytes. The 
expression and distribution of CD 146 protein in primary uveal melanoma tumours and 
normal human eyes, including the relationship ofCD146 expression to tumour type was 
also studied (Chapter 4). 
3. Investigate the in vitro effects of UV-B exposure on growth, viability and MMP 
production in uveal me_~anoma cell lines and primary uveal J?elanocytes (Chapter 5). 
·. 
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Chapter2 
General Materials and Methods 
·. 
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The studies in this thesis were performed according to the Declaration of Helsinki 
and with approval from the University of Sydney Human Ethics Committee. 
2.1 Primary Specimens 
Eyes enucleated for uveal melanoma (n=23 age range: 41 to 90 years) were 
routinely fixed in 10% neutral buffered formalin (NBF) and paraffin embedded 
(Anatomical Pathology, Prince of Wales Hospital) (Table 2.1). Postmortem eyes from 
donors ·cn=3; aged 39, 50 and 78 years old) obtained with consent from the Lions NSW 
Eye Bank, were fixed in 2% paraformaldehyde and NBF within 5-15 hrs after_ ~~th and 
paraffin embedded. These were used as controls in these studies. For all specimens, 
paraffm sections were cut at 8~Jm and collected on Super-Frost Plus (Menzel-Glaser) 
slides. 
Histopathology-Paraffin Sections 
The histopathology of uveal melanomas was assessed by Hematoxylin & Eosin (H&E) 
and Periodic Acid Schiff (PAS) staining as follows . 
. · 
H&E Staining '· 
Sections were dewaxed in xylenes and rehydrated through alcohols to water and 
stained with Mayer's haematoxylin (DAKO Australia Pty Ltd) for 2 mins, followed by 1% 
eosin for one min. Stained sections were subsequently dehydrated through alcohols and 
xylenes, then coverslipped in DePeX (BDH Pty Ltd). 
PAS Staining 
Sections were dewaxed and rehydrated prior to incubation in 0.5% periodic acid 
solution for 10 mins. Sections were then stained with Schiffs reagent at room temperature 
(RT) for 15-30 mins, rinsed in 3 changes of freshly prepared 0.4% sodium metabisulphite 
for 4 mins each until the pink reaction product reached the desired density. After a further 
rinse in water to remove excess stain, sections were dehydrated, mounted in DePeX and 
coverslipped. 
Table 2.1: Uveal Melanoma Characteristics 
Spe.cimen Sex Age Cell type *Treatment Time from 
(years) detection to 
enucleation 
1 M 41 Spindle B No Unknown 
2 M 43 SpindleB No 72 months 
3 M 52 S_pindle B No Unknown 
4 M 49 Mixed No 10 months 
5 F 60 Mixed No 1 month 
6 M 64 Mixed No ·~ I_~onth 
7 M 71 Mixed No 5 months 
8 F 74 Mixed No 1 year 
9 F 82 Mixed No 2 years 3 months 
10 M 90 Mixed No 0.5 month 
11 M 66 Mixed-spindle No 5.5 months 
predominant 
12 F 43 Mixed-spindle B No 1.5 months 
predominant 
13 M 53 Mixed-spindle B No 1 month 
. predominant 
14 M 58 Mixed-spindle B No 1 year 
p_redominant 
15 F 55 Mixed-spindle A&B No 4 months# 
predominant 
16 F 63 Mixed-epithelioid No 6 months 
predominant 
17 F 85 Mixed-epithelioid No 7 months 
predominant 
18 M 61 Mixed + balloon Plaque 3 years 10 
cells months 
19 M 62 Spindle Plaque 5 years 1 month 
20 F 68 Spindle Plaque 12 years 
21 M 77 Mixed Plaque 1 year 2 months 
22 F 81 Epithelioid Plaque 1 year 11 months 
23 F 85 Mixed Plaque 11 years 9 
months 
~ * 1125 plaque therapy 
~ 
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Immunohistochemistry 
Sections were stained with various antibodies (Table 2.2). A summary of the 
method used for single immunolabeling is shown in Figure 2.1. Paraffin sections were 
dewaxed, rehydrated and rinsed in 0.1 M phosphate buffer with 0.9% sodium chloride 
(PBS, pH 7.4). Antigen retrieval was used to expose masked antigens; sections were 
incubated in 0.01 M citrate buffer (pH 6) at 80°C for 15 mins, and then allowed to cool to 
40°C, before rinsing in PBS for 10 mins. This was followed by immersion in 5% H202 for 
5 mins to block endogenous peroxidase activity. The sections were rinsed in PBS for 10 
mins then circled with Dako pen (DAKO Australia Pty Ltd), incubated 1n l 0% serum 
(normal sheep serum [NSS], normal donkey serum [NDS] or normal goat serum [NOS] 
depending on the species in which the secondary antibody was raised in) at room 
temperature (RT) for 20 mins (Fig 2.1). The sections were then incubated in primary 
antibodies for 48 to 72 hrs at 4 oc (Fig 2.1 ). Foil owing a 20 min rinse in PBS on a shaking 
table, sections were then incubated in the appropriate secondary antibody for 1 hr at RT 
(Table 2.3, Fig 2.1); rinsed in PBS for 20 mins on shaking table, then incubated in 
ExtrAvidin peroxidase (Sigma) for 1 hr (Table 2.4). Sections were further rinsed in PBS 
prior to visualizat~on'of antibody binding using Vector NovaRED substrate (Vector Labs 
Pty Ltd) (Ta~le 2.4). The sections were counterstained in he~atoxylin for 10-15 seconds, 
dehydrated through alcohols and xylenes, mounted in DePeX and coverslipped. 
2.2 In-Vitro Studies 
Cell Lines 
Ten cell lines were kindly provided as follows: OCM-1, -3 & -8 (Dr J. Kan-
Mitchell, Karmanos Cancer Institute, Department of Pathology and Immunology, Wayne 
State University, Detroit); OMM-1 (Dr G.P. Luyten, Erasmus University, Rotterdam), 92-
1 (Dr M.J. Jager, Leiden University Medical Center, Leiden); Mel202 (Dr B. Ksander, 
Schepens Eye Research Institute, Boston) & OCM-1A, C918, MUM2B & MUM2C (Dr 
M.J. Hendrix, Children's Memorial Research Center, Northwestern University, Chicago) 
Uveal (OCM-1, -3, -8, 92.1, Mel202, C918, OCM-1A) and metastasis-derived 
(OMM-1, MUM2B, MUM2C) cell lines were maintained in either RPMI-1640 medium 
(OCM-3 and -8, Mel202, 92-1, C918, MUM2C, MUM2B) or Dulbecco's Modified 
Eagle's Medium (DMEM) (OCM-1A, OCM-1 and OMM-1) supplemented with 10% heat 
Table 2.2 P · 
--- --- --~- -------
tibod' 
-------- -----
Antibody_ S]_)_ecies Manufacturer Dilution 
Melanoma Ab-3 (HMB45/HMB50) Mouse NeoMarkers 1:50 
Vimentin monoclonal Rabbit NeoMarkers 1:500 
Vimentin monoclonal Mouse Dako 1:50 
Anti-human fibroblast Mouse Dako 1:25 
a-smooth muscle actin Mouse Dako 1:40 
Glial fibrillary acidic protein (GF AP) Mouse NeoMarkers 1:100 
MMP-9p_olyclonal _(latent/active) Rabbit NeoMarkers 4gg/ml 
TIMP-3 Ab-1 monoclonal Mouse Calbiochem 2~g/ml 
CD146 Goat R&D S_y_stems 2_1.1.g/ml 
CD146 Goat SantaCruz - 1:500 
GAPDH Mouse Ambion O.SJ..Lg/ml 
Mouse immunoglobulins Mouse Dako 1:100 
Rabbit immunoglobulins Rabbit Zymed 2J..Lg/ml 
_ . Qoa! illU11unogloh•:!lins. · ·~·- _ Go'!t_ -~ ·~ed _ _ _2jJg./gll ~ 
Table2.3 S 
- - -- - - -- -
-. -
d tibod' 
· - . 
Antibody Species Manufacturer Dilution 
Alexa-488 conjug~ted anti- Goat Mole((ular Probes 1:1000 
mouse 
Alexa-488 conjugated anti- Goat Molecular Probes 1:1000 
rabbit 
Alexa-488 conj~.zated anti-goat Rabbit Molecular Probes 1:1000 
B1otinyJated anti-mouse lg Sheep Amersham Pharmacia Biotech 1:100 
Biotinylated anti-rabbit lg Donkey Amersham Pharmacia Biotech 1:100 
Biotinylated anti-goat lg Rabbit Zymed 1:200 
HRP-conjugated anti-goat lgG Rabbit Bethyl Laboratories 1:12,500 
HRP-c()njl1gated_jllltj-tllouse Jg~ ~ Go!\1_ 
~ ·--
-~ U.QS!ate_~ 
-----
1 :lQ,OOQ~ 
Table 2.4 Others 
Name Manufacturer Dilution ! 
·. 
ExtrA vidin-peroxidase Sigma 1:250 I 
Vector NovaRED substrate kit Vector Labs N/A 
Hoechst Bis-benzimide 33258 Molecular Probes 300nM I 
Antigen retrieval 
(in 80°C citrate buffer) 
l 
Peroxidase blocking with 5°/oH20 2 (to reduce endogTous peroxidase activity) 
Blocking with serum 
(To reduce non-specific binding) 
l 
1 o Ab incubation 
(72hrs @ 4°C) 
l 
Biotinylated 2° Ab incubation 
(lhl@ RT) 
..1_ 
± ......._ 
ExtraAvidin peroxidase-conjugate (lhr @ RT) 
Vector NovaRED 
(2 mins) 
Counterstain, Dehydrate & Coverslip 
Figure 2.1 
Immunohistochemistry protocol for single labell ing using 
biotinylated secondary antibody and Vector NovaRED 
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inactivated foetal bovine serum (FBS), 2 mM glutamine, 50 IU/ml penicillin and 50 
~g/ml streptomycin. 
All ceU lines were grown in 75cm2 cell-culture flasks (NUNCLON Surface, 
NUNC), in a humidified incubator with 5% C02. For experiments, cells were detached 
using 0.25% trypsin/0.1% EDTA for 2 mins, deactivated with culture medium with 10% 
FBS, centrifuged for 5 mins at 290 g and 20°C. The pellet was resuspended in 4-5 ml 
culture medium, cell number and viability was assessed using 0.4% Trypan Blue and a 
hemocytometer counting chamber. 
Human Uveal Melanocvtes 
Human uveal melanocytes were isolated from eyes (n=5; average postmortem 
delay approximately 16 hrs), obtained with consent from the Lions NSW Eye Bank 
(Sydney, Australia). The method for isolation, purification, and cultivation of human 
uveal melanocytes was based on the methods of Hu et al (1993), with minor 
modifications. Briefly, a circumferential incision was made in the anterior portion of the 
eye and cornea, anterior sclera, lens, iris, ciliary body, vitreous, retina as well as ora 
serrata were removed Jeaving the retinal pigmented epithelium (RPE) and choroid within 
' ' 
the eyecup. The eyecup was filled with 0.25% trypsin/0.1% EDTA and incubated at 37°C 
incubator for 45 mins. The-trypsin solution-..in the eyecup was gently pipetted to release 
the RPE. The trypsin/cell solution was removed and the eyecup rinsed with PBS twice. 
The choroid was then separated from the sclera, cut into 4 or 5 pieces and immersed in 
0.25% trypsin/0.1% EDTA solution and incubated with shaking at 4°C for 18 hrs, then 
incubated for a further hr at 37°C. Trypsin activity was deactivated by 'adding 1 ml of 
Ham's Fl2 medium with 10% heat-inactivated FBS. The supernatant/released cells were 
collected and centrifuged for 5 mins at 290 g and 20°C. The pellet was resuspended in 1 
m1 melanocyte growth medium (MGM) [Ham's F12 supplemented with 10% FBS, 2 mM 
L-glutamine, 50 IU/ml penicillin/50 ~g/ml streptomycin and 10 ng/ml cholera toxin 
(Sigma Chemical Co., USA), lOOnM PMA (phorbol12-myristate 13-acetate) and, 0.1mM 
isobutylmethylxanthine (IBMX) (Sigma)] and seeded into a 6-well plate (NUNCLON 
Surface, NUNC). This procedure was repeated a further 2 times, incubating the pieces of 
choroid in 1.2 U/ml dispase II (neutral protease) (165859, Roche) and 0.5 mg/ml 
- collagenase (Type-lA; made from clostridium histolyticum, Sigma-Aldrich) at 37°C for 1 
hr. 
Figure 2.2 
Uveal melanocytes immunolabelled with Melanoma Ab-3 (A), non-specific lgG I (B) 
antibody, vimentin (C) and human prolyl 4-hydroxylase (fibroblasts) antibody (D). 
Figure 2.3 _ 
Inverted microscopy of uveal (A-G) and 
meta~tatic (H-J) cell lines. 
A.OCM-1 F.OCM-lA --
B.OCM-3 G.C918 
C.OCM-8 H.OMM-1 
D.92-l I.MUM2B 
E.Mel202 J .MUM2C 
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Figure 2.4 
Cultured human uveal melanocytes 
A. Freshly extracted melanocytes (PO). 
B. Melanocytes (P2) after a PBS wash, and grown for a few weeks. 
C. Mix of pigmented and depigmented melanocytes in a colony. 
D. Melanocytes with bipolar processes. 
E. Melanocytes with multiple processes. 
F. Melanocyte with dendritic processes. 
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After 48 hrs, cultures were washed gently with warm PBS to remove debris and 
red blood cells. A further 1.5 ml of MGM was added. Cultures were allowed to grow for 
2-4 weeks. Cells were detached using 0.25% trypsin/0.1% EDTA for 2 mins, deactivated 
with Ham's F12 medium with 10% FBS, centrifuged for 5 mins at 290 g and 20°C. Cells 
were resuspended in 1ml MGM and placed in 25cm2 flask (NUNCLON Surface, NUNC) 
with 6 ml MGM. In general, primary uveal melanocytes grew more slowly than 
transformed cell lines, required medium renewal twice per week and were passaged on 
average 7-10 days. 
To assess the purity of the melanocytes, -104 cells/well were seed~d onto sterile 
glass coverslips and immunolabelled. The following primary antibodies were used: mouse 
anti-human fibroblast (prolyl 4-hydroxylase) (1 :25; Dako, Denmark), a.-smooth muscle 
actin (1:40; pericytes, Dako), and Melanoma Ab-3 (1:100; antibodies to melanoma and 
melanocyte-specific antigens HMB-45 and HMB-50, NeoMarkers, USA); and mouse 
' anti-swine vimentin (1: 1 00; Dako ). A non-specific IgG 1 isotype control (1: 1 00; Dako, 
Denmark) was used to confirm specificity of immunolabelling. The primary melanocyte 
cultures used were >95% pure, confirmed by Melanoma Ab-3 immunoreactivity (Fig 2.2), 
and an absence of hw:nan prolyl 4-hydroxylase (fibroblas~) immunolabelli.ng (Fig 2.2). 
Cultures with >95% purity were subsequently passaged when they became semi-confluent 
and used for experiments or frozen. Passage (P) 1 to 3 cells were used for all experiments. 
Photomicrographs were taken of cultured uveal melanoma cell lines (Fig 2.3) and 
uveal melanocytes (Fig 2.4) with an inverted phase-contrast microscope (Olympus IX70, 
Japan), to document cell growth, morphology, and presence or absence of contaminating 
cells. Several morphological phenotypes were observed for melanocytes including bipolar, 
multiprocessed, pigmented and dendritiform (Fig 2.4). These may represent different 
stages of growth in culture, or even suggest subpopulations of melanocytes perhaps 
including progenitor cells (Xu, et al., 2007). 
·. 
Immunocytocltemistry 
Uveal melanocytes and uveal melanoma cells were stained with various antibodies 
' 
(Table 2.2), and summary of the method used for immunocytochemical staining is shown 
_ in Figure 2.5. Sterile glass coverslips were seeded with 2.5-5x104 cells and incubated at 
37°C for 3 to 5 days. Coverslips were fixed in 2% paraformaldehyde in PBS (pH 7.4) for 
10 mins, rinsed in PBS, and incubated for 20 mins at RT with 10% serum (dependent on 
Cells seeded on to 
sterile glass coverslip 
1 
Fixed for 1Om ins @ RT 
1 
Blocking with NGS 
(20mins @ RT) 
1 
1 o Ab incubation 
(24hrs @ 4°C) 
1 
Alexa-488 conjugated 
2° Ab incubation 
(lhr l RT) 
Hoechst Bis-benzimide 
33258 (nuclei) incubation 
(Briefly @ RT) 
1 
Mount in glycerol 
& Coverslip 
Figure 2.5 
~ 
~ 
~ 
~ 
im 
im 
Immunocytochemistry protocol for single labelling, visualised using 
Alexa-488 conjugated secondary antibody 
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the species of the secondary antibodies) to reduce nonspecific binding (Fig 2.5). Cells 
were incubated in primary antibodies overnight at 4°C, and labelled for 
immunofluorescence using the appropriate Alexa-488 conjugated secondary antibody 
(1:1000, Molecular Probes, USA) for 1 hr at RT. Nuclei were stained with Hoechst Bis-
benzimide 33342 (Molecular Probes, USA) (Fig 2.5). Coverslips were rinsed with PBS, 
mounted in glycerol, and viewed using either inverted fluorescence microscopy (Olympus 
IX70, Japan) or a LSM 5 PASCAL laser scanning confocal microscope (Carl Zeiss, 
Germany). For inverted microscopy, images were collected using OLYMPUS DP 
Controller software and exported to Photoshop for analysis. For confocal microscopy, 
images were collected either as single scans or as multiple Z-stacks, using. LSM 5 
PAS CAL Version 3.2 SP2 software and exported to Photo shop for analysis. 
·. 
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Chapter 3 
Expression and Distribution ofMMP-9 & TIMP-3 
·. 
in Uveal Melanoma 
Results from this study are included in the publication: K Lai, RM Conway, R 
Crouch, MJ Jager and MC Madigan: Expression and Distribution ofMMPs and TIMPs in 
Human Uveal Melanoma. Exp Eye Res. PMID: 18423620, Mar 16 2008. 
Factors Involved in the Pathogenesis of Human Uveal Melanoma 34 
3.1 Introduction 
As discussed in Chapter 1.3, MMPs and TIMPs are implicated in the development 
and growth of uveal melanoma. This topic was originally studied during Honours and 
demonstrated specific distributions of MMP-1, -2, -19, MT1-MMP and TIMP-2 in a 
series of uveal melanomas, supporting their role in tumour growth and invasion (Lai, 
2002). This included documenting expression in tumour cells, vasculature and stromal 
cells, as well as topographical variations throughout uveal melanomas. 
The current study expands these original observations to include_ MMP-9 and 
-. 
TIMP-3. Several studies suggest that latent MMP-9 (along with latent MMP-2) is 
associated with a higher incidence of metastatic disease in uveal melanoma (El-Shabrawi, 
et al., 2001; Rao, et al., 2004). Epithelioid melanomas or the epithelioid portion of mixed-
cell melanomas have been found to predominantly express latent MMP-9 and patients 
with tumours expressing TIMP-1 and TIMP-2, the main physiological inhibitors of MMP-
2 and MMP-9 respectively, have a better survival rate (El-Shabrawi, et al., 2001). A small 
series of mixed morphology uveal melanomas were also found to express MMP-2, -9, -13 
and MTl-MMP (Lave_r, 2002). 
Downregulation of TIMP-3 has !ecently been shown to be associated with the 
invasiveness of uveal melanomas (van der Velden, et al., 2003) (see Chapter 1.2). A 5-
fold decrease in TIMP-3 gene expression is reported in metastatic uveal melanoma cells 
when compared to primary uveal melanoma cells, regulated by DNA methylation (van der 
Velden, et al., 2003). Furthermore, a relationship between TIMP-3 protein expression and 
chromosome 3 status in uveal melanoma has yet to be established (Nareyeck, et al., 2005). 
Aim 
The expression of MMP-9 and TIMP-3, including regional differences in 
immunolabelling of tumour cells, stroma and the vasculature, has not been fully described 
in uveal melanoma. To better understand the dynamics of the tumour microenvironment, 
the distribution of MMP-9 and TIMP-3 pattern .in different regions of uveal melanomas 
and adjacent choroid was investigated. 
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3.2 Materials and Methods 
Parliffin Sections 
Paraffin sections were cut from eyes enucleated for uveal melanoma, and normal 
eyes as described in Chapter 2.1. Uveal melanoma specimens included 18 untreated 
melanomas and 5 1125-treated melanomas (Table 2.1), and the majority of tumours were 
located in the choroid posterior to the equator. Normal human eyes (n=3; aged 39, 50 and 
78 years), provided by the Lions NSW Eye Bank with consent and ethical approval, were 
fixed in 1 0% neutral buffered formalin, paraffin-embedded, and used as-controls (see 
----
Chapter 2.1). 
Immunohistochemistry 
As described in Chapter 2.1, sections were immunolabelled with antibodies to 
MMP-9 and TIMP-3 (Table 2.2) and visualized with peroxidase and Vector NovaRed 
(Vector Laboratories). 
Immunostaining of melanomas was graded in masked fashion by 2 independent 
observers (KL, ~M) using a semi-quantitative scale where 0 = none, 1 = weak (low 
intensity staining of tumour cells regardless of%, and medium intensity staining of ~20% 
cells); 2 = moderate (medium intensi~ staining of >20% tumour cells, high intensity 
staining of ~20% tumour cells), and 3 =strong (high intensity staining of >20% tumour 
cells). Differences in grading were resolved by joint review and if necessary, consultation 
with a third independent observer. The grading of the 2 observers was significantly 
correlated (p<0.001; Kendall's . rank correlation). Non-parametric linear regression 
analysis was used to test for an association between cell type (1 = spindle; 2 = mixed or 3 
= epithelioid), MMP-9 and TIMP-3 immunolabelling (grades 0 to 3), and maximum 
tumour height (in mm). 
The distribution and intensity of MMP-9 and TIMP-3 immunostaining in retina 
overlying tumours and in regions of choroid and retina without melanoma, as well as in 
normal choroid and retina, was also assessed. 
Additionally, control and melanoma-associated attached retina, as well as 
detached retina were double immunolabelled with antibodies to MMP-9 (raised in rabbit) 
and glial fibrillary acidic protein (GF AP) (NeoMarkers; raised in mouse, 4J,Lg/ml). Briefly 
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paraffin sections were dewaxed, dehydrated and antigen retrieval performed as for single 
immunolabeling. Blocking of endogenous peroxidase activity was not required. The 
sections were then circled with Dako pen, incubated with 10% NGS at room temperature 
for 20 mins. The sections were incubated in a mixture of MMP-9 and GF AP antibodies 
for 72 hrs at 4 °C. After rinsing in PBS on a shaking table for 20 mins, sections were 
incubated in a mixture of anti-rabbit Alexa-488 and anti-mouse Alexa-594 (Molecular 
Probes, USA) for an hr at room temperature and protected from light exposure. After 
rinsing with PBS, sections were mounted in glycerol, coverslipped and viewed with a 
Zeiss LSM 5 Pascal laser scanning confocal microcope and LSM 5 Pascal Image software. 
Multichannel excitation bleedthrough was minimized by using fluorochromes Wi~ a large 
difference in· peak excitation ( 488nm and 594nm respectively). Emission bleedthrough 
was minimized by Multitracking, where signal crosstalk between neighbouring channels 
was corrected by performing a sequential image capture routine. This process combined 
images acquired with a single excitation beam/single detection channel acquisition 
process. Tiris methodology was employed to correct for the effects of emission crosstalk. 
'• 
•, 
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3.3 Results 
Tumour Histopathology 
The histopathology of uveal melanomas was assessed from H&E and PAS stained 
sections as described in Chapter 2.1. Uveal melanomas displayed spindle cell (n=S/23), or 
mixed and epithelioid cell (n=l7/23) morphology (Fig. 1.1.3A & B). Tumours ranged 
from 5 to 24mm maximum diameter and 2 to 14mm maximum height (Chapter 2.1, Table 
2.1a). Rupture of Bruch's membrane and dome-shaped tumours were observed in 7/23 
(30%) of specimens. Melanomas had low mitotic rates (n=13; S 5 mi~<?seslhigh-power 
field). Small and large blood vessels were observed throughout all tumours (Fig. 1.1.4A). 
I 125 -treated melanomas displayed areas of scarring with remnants of tumour cells, necrosis 
and increased numbers of leukocytes. For untreated specimens, extracellular matrix (ECM) 
patterns in PAS-stained sections were classified as described previously (Folberg, et al., 
1992, 1993), with the following patterns observed: vessel lumens only (Fig. 1.1.4A), 
straight channels (Fig. 1.1.4B), incomplete loops (Fig. 1.1.4C) and complete loops and 
networks (Fig. 1.1.4D). Incomplete loops, complete loops and networks were seen in 1/3 
spindle cell tumours and 8/15 mixed and epithelioid tumours. ECM patterns were not 
assessed in I125 -treit~d melanomas due to the presence of rad~ation-associated pathology. 
Immunohistochemistry 
Distinct patterns of immunolabelling for MMP-9 and TIMP-3 were seen in uveal 
melanomas (see below; Fig. 3.1 & 3.2). Overall no significant association was found 
between tumour cell type and expression of MMP-9 and TIMP-3 (P>0.05; non-parametric 
regression, Table 3.1 ). The majority of specimens displayed much reduced 
immunoreactivity for MMP-9 and TIMP-3 at the tumour-scleral interface (TSI), with a 
band of increased immunolabelling immediately adjacent to this region (Fig. 3.1). 
Sections incubated in either rabbit Igor non-specific mouse anti-IgG1 as controls showed 
no immunolabelling (Fig. 3.1F & 3.2D respectively). 
Figure 3.1 
Uveal melanoma immunolabelled for MMP-9 and Ig control. A. General 
MMP-9 immunolabelling of tumour cells. B. The tumour scleral interface 
shows no MMP-9 immunolabelling. C&D. Tumour cells and vasculature 
display MMP-9 expression. Intravascular leucocytes are also MMP-9-
positive (D; arrow). E. Extravascular matrix patterns immunolabelled for 
MMP-9 (arrowheads; cfPAS staining, Fig 1.1.4). F. Sections incubated 
with rabbit Ig control. (TSI - tumour scleral interface, bv - blood vessel. 
Scale bar = 50J.1m) 
Figure 3.2 
Uveal melanoma immunolabelled for TIMP-3 and Ig control. A. General 
TIMP-3 immunolabelling of tumour cells. B. Localised TIMP-3 
immunolabelling in peripheral tumour(*). C. TIMP-3 immunostaining of 
melanoma cells (mostly epithelioid) surrounding vasculature (arrows). D. 
mouse IgG I isotype control showed no reactivity. (bv - blood vessel. TSI 
- tumour scleral interface. S - sclera. Scale bar = 50J.1m) 
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Distribution of MMP-9 in Primary Uveal Melanoma 
The m_ajority of tumours showed moderate to strong cytoplasmic MMP-9 
immunolabelling (74% ?:Grade 2, Table 3.1; Fig. 3.1). There was less difference in levels 
of immunostaining of central tumour and regions adjacent to the TS1 for MMP-9 than for 
other MMPs, as observed previously (Lai, 2002; Lai, et al., 2007). Heterogeneous MMP-9 
immunolabelling of tumour vessels was observed (Fig. 3.1C&D), and intravascular 
leukocytes expressed MMP-9 (Fig. 3.10). Patterns of MMP-9 expression similar to the 
PAS-positive extravascular matrix patterns described above (Fig. 3.1 E cfFig. 1.1.4C & D) 
were seen in 4/23 mixed/epithelioid tumours. For the 1125 treated specimens, MMP-9 
immunolabelling was observed in the leukocytes and localised near the areas of necrosis 
and scarring. 
Table 3.1 MMP-9 & TIMP-3 Immunostaining of Uveal Melanomas 
n <Grade 28 ?: Grade 28 
MMP-9 23 6/23 (26%) 17/23 (74%) I 
I 
TIMP-3 23 11/23 (48%) 12/23 (52%) ! 
- - - --- --
------·- - ---- --
8Average semi-quantitative grade: O=none, 1= weak (low intensity staining of tumour 
cells regardless of%, and medium intensity staining of :QO% cells); 2=moderate (medium 
intensity staining of >20% tumour cells, high intensity staining of ~20% tumour cells), 
and 3= strong (high intensity staining of>20% tumour cells). 
Distribution of TIMP-3 in Primary Uveal Melanoma 
Cytoplasmic TIMP-3 immunostaining was expressed at moderate to high levels~ 
grade 2) in -50% of tumours (Table 3.1, Fig 3.2). Peripheral tumour regions (excluding 
the TS1) showed localized strong TIMP-3 immunolabelling in -25% of cases (Fig 3.2B). 
In 5/23 tumours, local areas of tumour cells surrom1ding blood vessels had intense' TIMP-
3 immunostaining, although the vasculature did not express TIMP-3 (Fig 3.2C). For the 
1125 treated specimens, TIMP-3 also appeared to· be localised in tumour cells near areas of 
necrosis and scarring, but with lower intensity than MMP-9. 
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Distribution of MMP-9 and TIMP-3 in Control & Uveal Melanoma Associated Retina 
· In control and melanoma eyes, weak to moderate MMP-9 immunolabelling was 
observed throughout the retina including the ganglion cell layer, retinal blood vessels, 
inner and outer plexiform layers, some Muller cells processes, retinal pigmented 
epilthelium (RPE), choriocapillaris and large choroidal blood vessels (Fig 3.3 A & B). 
However, in some regions of detached retina associated with uveal melanoma, increased 
expression ofMMP-9 was seen localised in the macroglia (i.e Muller cells and astrocytes) 
and plexiform layers (Fig 3.4 A & B). Additionally this localisation was also observed in 
some regions of retina overlying the tumour (Fig 3.4 C & D). Control and melanpp1a eyes 
displayed moderate to strong TIMP-3 expression in Bruch's membrane and drusen (Fig 
3.3 D & E). Little or no TIMP-3 immunolabelling was observed in the retina (Fig 3.3D & 
E). 
To further explore the MMP-9 expression in the macroglia associated with retinal 
detachment, control (n=3) and melanoma-associated retinae (n=7) were double-
immunolabelled with MMP-9 and GF AP antibodies. GF AP is known to be up-regulated 
in activated MUller c~lls in retinal pathologies including detachment (Erickson, et al., 
1987). The detached retina was generally disorganised, with l9ss of the outer plexiform 
layer, much reduced inner plexiform layer and possible loss of neurons (Fig 3.4B). In both 
control and melanoma-associated attach~d retinae, MMP-9 immunolabelling was similar 
to that seen in immunoperoxidase labelled sections while GFAP was observed in the 
macroglia (Fig. 3.5A). In some regions of the detached retinae, MMP-9 and GFAP were 
co-localised within the macroglia (Fig 3.5 B & C). 
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Figure 3.3 
Control and uveal melanoma retina immunolabelled for MMP-9, TIMP-3 and lg control. A&B. MMP-9 
immunolabelling of blood vessels, ganglion cell layer, inner and outer plexiform layers, choriocapillaris and 
RPE in (A) control and (B) melanoma eyes. D&E. TIMP-3 immunolabelling of Bruch's membrane (arrows) in 
(D) control and (E) melanoma eyes. TIMP-3 immunolabelling of drusen is also observed in a melanoma eye 
(arrowhead). C&F. Mouse IgG 1 isoptype control (C) and rabbit lg control (F) showed no reactivity. (bv -
blood vessel, GCL- ganglion cell layer, IPL- inner plexiform layer, OPL- outer plexiform layer, RPE- retinal 
pigmented epithelium, CC- choriocapillaris. Scale bar = lOOJJ.m) 
~ 
Ex 
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Figure 3.4 
,NFL 
I I ) . 
MMP-9 immunolabelling in detached retina associated with melanoma. 
A. MMP-9 is seen in presumptive Muller cell processes extending from 
the inner retina to the outer nuclear layer (arrowheads). B. Localised 
MMP-9 in the astrocytes and Muller cells. C. MMP-9 localised in the 
astrocyte (arrows) in the retina overlying the tumour. D. In another retina 
overlying the tumour, increased MMP-9 immunolabelling is seen in both 
astrocytes (arrows) and end processes of Muller cells (arrowheads). (NFL 
- nerve fibre layer, GCL - ganglion cell layer, INL - inner nuclear layer, 
ONL - outer nuclear layer, Ex - exudate, T - tumour. Scale bar = 50j..tm) 
Figure 3.5 
MMP-9 (green) and GF AP (red) double-immunolabelling in retina. A. Attached retina associated with melanoma 
displayed similar MMP-9 expression to immunoperoxidase stained sections (Fig 3.3). GF AP is observed in the 
macroglia (predominantly astrocytes & some MUller cell processes). B & C. Regions of detached retina displayed 
co-localisation of MMP-9 & GFAP in astrocytes (arrow heads) and MUller cell processes (arrows) extending 
from inner to outer retina. In B, the distribution of GFAP in the detached retina is seen with the red channel only. 
(bv - blood vessel, GCL - ganglion cell layer, IPL - inner plexiform layer, OPL- outer plexiform layer) 
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3.4 Discussion 
· Distinct patterns of immunostaining for MMP-9 and TIMP-3 were observed in 
uveal melanomas, although a statistically significant association between tumour type and 
expression of MMP-9 and TIMP-3 was not found, most probably related to the small 
number of specimens. Survival analysis for these patients was not possible as tumours 
were collected recently and this information was not available. 
Distribution of MMP-9 in Uveal Melanoma 
In the present study, heterogeneous MMP-9 expression was observed_ in both 
melanoma cells and tumour blood vessels. Moderate to high levels of MMP-9 expression 
were observed in the majority of all uveal melanoma specimens, consistent with previous 
studies (El-Shabrawi, et al., 2001; Laver, 2002; Rao, et al., 2004). As mentioned in 
1 
Chapter 1.1.4B angiogenesis, plays an important role in the development of uveal 
melanoma (Folberg, et al., 1993; reviewed Jager, et al., 2004). Uveal melanomas also 
display an additional microcirculation - extravascular matrix channels (vasculogenic 
mimicry) - produced by tumour cells themselves (see Chapter 1.1.4B) (Folberg, et al., 
2004; Maniotis, et al., 1999). Angiogenic factors including vascular endothelial growth 
factor (VEGF) and bFGF have been reported to be expressed in uveal melanoma cells, 
tumour vasculature and cell lines (Abdel-Rahman, et al., 2005; Boyd, et al., 2002; 
Missotten, et al., 2006; Notting, et al., 2006). 
MMPs have been implicated in both angiogenesis and vasculogenic mimicry 
related to their ability to degrade vascular basement membranes as w.ell as to activate 
growth factors including VEGF, bFGF and TGF-~ (Iida, et al., 2007; Seftor, et al., 2001; 
Raffetto, et al., 2008). A recent study also showed that VEGF-A and MMP-9 were 
associated with metastatic uveal melanoma (Sahin, et al., 2007). MMP-2, -9 and MT1-
MMP have been reported to facilitate tumour angiogenesis, cell migration and invasion 
(Egeblad, et al., 2002; Hofmann, et al., 2000; Sato, et al., 1994; Stamenkovic; 2000). 
Human endothelial cells have been found to constitutively secrete pro-MMP-2, further 
supporting a role ofMMP-2 in regulating angiogenesis (Lafleur, et al., 2001; Nguyen, et 
al., 2001). Consistent with these observations, (latent and active) MMP-2 and MTI-MMP 
expression were previously observed in tumour vasculature (Lai, et al., 2007), as well as 
heterogeneous MMP-9 expression in the present study. 
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Gene microarray analyses of aggressive uveal melanoma cell lines have also found 
highly increased levels of:MMP-1, -2, -9 and MTl-MMP, and laminin 5y2 compared with 
poorly aggressive cell lines (Seftor, et al., 2001). The matrix networks formed by these 
aggressive melanoma cells, when grown in collagen I gels were immunolabelled for these 
MMPs (Seftor, et al., 2001). MMP-2 and MTl-MMP also cleave laminin 5y2 to produce 
pro-migratory fragments critical for the formation of laminin-rich PAS-positive 
extravascular matrix networks (vasculogenic mimcry), characteristic of aggressive uveal 
melanomas (Folberg, et al., 1992; Hendrix, et al., 2003; Seftor, et al., 2001). Although 
evidence of MMP-9 expression similar to PAS-positive patterns was observed in several 
tumours in the present study, no such patterns were found for MMP-2 andMTl-MMP in 
the previous study (Lai, et al., 2007). 
Distribution of T/MP-3 in Uveal Melanoma 
TIMP-3 can regulate various MMPs and tumour invasion, as well as inhibiting 
angiogenesis and inducing apoptosis (Ahonen, et al., 1998; Qi, et al., 2003; Smith, et al., 
1997). As such, loss of TIMP-3 may contribute to tumour growth, and TIMP-3 
downregulation associated with changes in methylation has been found in several cancers 
including uveal melanoma (Mino, et al., 2007; Mylona, et al., 2006; van der Velden, et al., 
2003). Furthermore, gene microarray studies have indicated a significant inverse 
relationship between TIMP-3 mRNA and 'chromosome 3 status, where no expression of 
TIMP-3 was found in 6/10 tumours with monosomy 3 (associated with metastases and 
poor prognosis) (Nareyeck, et al., 2005). 
Considerable variation has been reported in levels and extent of TIMP-3 
immunostaining in primary uveal melanomas (Nareyeck, et al., 2005; van der Velden, et 
al., 2003). In one study, an association between TIMP-3 and tumour histopathology 
(number of mitoses, cell type and presence of PAS+ loops and networks) could not be 
confirmed (van der Velden, et al., 2003). However, a trend between TIMP-3 protein 
. 
expression and tumour cell type (p=O.ll) and loops and/or networks (p=0.06) has been 
reported, with TIMP-3 seen in 50% of tumours, of which only 3 had > 5% TIMP-3 
positive tumour cells (Nareyeck, et al., 2005). In the present study, heterogeneous TIMP-3 
expression was observed in all uveal melanomas, although no association was found 
between tumour type and level of expression. 
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Angiogenesis involves generating new blood vessels from the pre~existing vessels 
and is a critical event during uveal melanoma development (reviewed Jager, et al., 2004). 
Angiogenesis requires various factors including VEGF and MMPs (Pepper, et al., 1996); 
(review Jager, et al., 2004). Proteinase and collagenase activities are tight.ly regulated 
during angiogenesis, otherwise they can lead to vascular regression and haemorrhage 
(reviewed Oh, et al., 2001; Saunders, et al., 2006)). An in vivo and in vitro study 
demonstrated that pericyte~derived TIMP~3 stablises vascular tube formation during 
angiogenesis (Saunders, et al., 2006). TIMP-3 has been suggested to interact with 
proteoglycans within the vascular basement membrane matrix, maintaining contact 
between pericytes and endothelial cells; this localisation of TIMP~3 has implications for 
vascular stabilization (Davis, et al., 2005; Saunders, et al., 2006). Furthermore, TIMP-3 
has also been shown to inhibit MMPs and VEGF-related angiogenesis (Egeblad, et al., 
2002; Qi, et al., 2003). In some tumours in the present study, tumour cells surrounding 
vessels displayed TIMP-3 but not in the tumour vasculature (Fig 3.2C). These 
observations and the previous studies discussed above, may suggest that TIMP-3 
produced by vascular-associated tumour cells plays a role in stabilising mature tumour 
vasculature, similar to pericytes in other systems (Saunders, et al., 2006). 
Distribution of MMP-9 and TIMP-3 in Retina and Choroid . 
Whether latent and active MMP-9 are expressed in the human retina remains 
controversial. Several studies have reported no latent and active MMP-9 
immunoreactivity in normal human retina while others have observed MMP-9 expression 
in the ganglion cell layer as well as cultured MUller cells and RPE (Ahir, et al., 2002; 
Limb, et al., 2002; Salzmann, et al., 2000; Sivak, et al., 2002; Webster, et al., 1999). In 
the present study both latent and active MMP-9 immunolabelling was observed in normal 
and melanoma eyes. There appeared to be no obvious differences in MMP-9 expression in 
normal retina and in attached retina associated with melanoma, suggesting that MMP-9 is 
likely to be involved in normal retinal physiology and angiogenesis. Other studies iQ. CNS, 
including retina, have suggested a physiological role for MMP-9 in maintaining neuronal 
integrity (Dzwonek, et al., 2004; Papp, et al., 2007). Furthermore, the MMP-9 antibody 
used in this study detected both latent and active forms and future studies comparing the 
distribution of latent and active MMP-9 separately, may further clarify its functional 
significance in normal retina. 
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In some regions of detached retina associated with melanoma, MMP-9 appeared to 
be localised predominantly in Muller cells. Muller cells stabilise the retinal architecture, 
provide structural support to retinal neurons and blood vessels and are involved in 
preventing aberrant photoreceptor migration into the subretinal space (Newman, et al., 
1996; reviewed Bringmann, et al., 2006). Physiologically, Muller cells maintain the 
homeostasis of the retinal extracellular environment including ions, water, 
neurotransmitter molecules and pH, provide nutrients to the retinal neurons and remove 
metabolic waste (reviewed Bringmann, et al., 2006; reviewed Reichenbach, et al., 2007). 
Muller cells are well known to become activated in response to retinal injury (reviewed 
Bringmann, et al., 2006; reviewed Reichenbach, et al., 2007). Furtherriiore, . they can 
proliferate and also act as progenitor cells following neurotoxic injury to the rat retina 
(Ooto, et al., 2004). MMP-9 in Milller cells has been suggested to constitute an early 
response to retinal pathology, including detachment (Limb, et al., 2002). Taken together, 
these observations suggest that MMP-9 may be involved in MUller cell activation in 
response to long-term serous retinal detachment associated with melanoma growth. 
In the normal human eye, TIMP-3 is expressed in the RPE and Bruch's membrane 
(Fariss, et al., 1997; Vranka, et al., 1997). Pathological.ly, TIMP-3 is as.sociated with 
Sorsby's retinal dystrophy, a hereditary macular disorder which leads to blindness in the 
third or fourth decade oflife (Weber, et al., 1994). In the present study, both normal and 
melanoma eyes expressed TIMP-3 in Bruch's membrane and RPE. Interestingly, TIMP-3 
expression in Bruch's membrane of melanoma eyes appeared to be uneven and punctated. 
This may be due to the physical rupture of Bruch's membrane by the tumour (see Chapter 
1.1.3). Another possibility may be that growth factors bound within the ECM are released 
from the matrix and activated, associated with melanoma growth and MMP production. 
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Chapter 4 
Distribution and Expression of CD146 in 
_ · Human Uveal Melanotn.a 
Results from this study are included in the publication: K Lai, V Sharma, MJ Jager, RM 
Conway, MC Madigan; Expression and Distribution ofMUC18 inHuman Uveal 
Melanoma. Virchows Archiv 451(5):967-76, 2007. 
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4.1 Introduction 
· As discussed in Chapter 1.3, the Ig superfamily protein CD146 is involved in 
tumour development and expressed in malignancies including cutaneous melanoma. 
Recent studies using 2-D gel electrophoresis found CD146 expression in several uveal 
melanoma cell lines (Pardo, et al., 2005, 2006). Moreover, cell lines with increased levels 
of CD146 protein also displayed an increased potential for in vitro invasiveness, 
suggesting an association between CD 146 and uveal melanoma growth (Pardo, et al., 
2006). CD 146 expression is also reported to be induced ( epigenetically) in poorly 
aggressive uveal melanoma cells (OCM-lA) grown in collagen I matrix pre-conditioned 
by aggressive metastatic uveal melanoma cells (MUM2B), further supporting a role for 
CD146 in uveal melanoma invasion (Seftor, et al., 2006). The expression and distribution 
of CD 146 in primary uveal melanomas remains to be established. 
Aims 
This study extended the in vitro observations in previous studies, to a series of 
uveal and metastasis-derived cell lines and primary uveal melanocytes using diagnostic 
RT-PCR, Western blotting and imrmmocytochemistry. Furthermore, the distribution of 
CD 146 protein in primary human uveal melanomas and normal eyes was studied using 
immunhistochemistry. 
·, 
; 
I 
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4.2 Materials and Methods 
In vitro Studies 
Diagnostic Reverse Transcription (RT)~PCR 
RT-PCR was performed on 7 uveal (OCM-1, -3, -8, 92.1, Mel202, C918, OCM-
lA) and 3 metastasis-derived melanoma cell lines (OMM-1, MUM2B, MUM2C) and 
cultured normal human uveal melanocytes (NHM; n=2). The methods for isolation and 
culture of primary uveal melanocytes have been described in Chapter 2.2. 
RNA Extraction 
Melanoma cells and human uveal melanocytes were seeded in 6-well plates at a 
density of 106 and 5x105 cells per well respectively. Melanoma cells were cultured for 24 
hrs while the uveal melanocytes required 2-3 days to become semi-confluent, as their 
growth rates are slower than melanoma cell lines (Chapter 2.2). RNA was extracted by 
lysing the cells directly in the well with 1 ml of Trizol (Invitrogen Life Technologies Pty 
Ltd). Cell lysates were collected by sterile glass pipette and transferred into a sterile 
Eppendorf tube and incubated for 5 mins, after which 20Q J,ll chloroform (per 1ml of 
Trizol) was added and the tube was shake-? vigorously for 15 seconds and left at RT for 3 
mins. Following centrifugation at 13,090 gat 4°C for 15 mins, the upper aqueous phase 
(RNA) was collected and transferred into sterile Eppendorf tube. RNA was precipitated 
by adding approximately 500 Jll cold isopropanol (per lml of Trizol). Samples were 
stored at -20°C for 20 mins; centrifuged at 13,000 g for 15 mins at 4°C. The supernatants 
were removed and the RNA pellet washed in 1ml cold 75% ethanol with vortexing and 
centrifuged at 7,500 gat 4°C for 5 mins. The supernatant was removed and the RNA air-
dried for approximately 20 mins. An appropriate volume of RNase-free water (I 0-30 J.tl) 
was added to the RNA, followed by incubation at 42°C for 1 0 mins to re-dissolve the 
. 
RNA. The RNA was quantified using a spectrophotometer (SmartSpec 3000, BIORAD) 
at 260 and 280 nm to determine purity and concentration. The A26012so of RNA ideally 
should be 1.8-2, however for human uveal melanocytes the A260/280 was affected by the 
presence of melanin (Dorrie, et al., 2006), and readings were usually lower; an A260t2so 
above 1.6 was found to be acceptable for melanocytes. 
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Reverse Transcription (RT) 
RNA was reverse transcribed to eDNA (single strand DNA) before polymerase 
chain reaction (PCR). For each sample, 3 ).lg RNA was mixed and centrifuged briefly with 
1 111 of lOmM DNTP mix and lJ!l Oligo (dT) (0.5 ).lg/J!l) (Invitrogen). Samples were then 
made up to 101!1 with DEPC-treated water, and placed immediately on ice. Samples were 
heated at 65°C for 5 mins and placed on ice for at least 1 min, then gently mixed with RT 
master mix (Table 4.1) and centrifuged briefly. For each eDNA sample, an RT minus 
control was included; the SuperScript III RT enzyme (Invitrogen) was omitted and 
replaced with DEPC-treated water (Table 4.1). 
Table 4.1: Master Mix for eDNA Transcription. 
R T master mix RT minus master mix 
10XRT buffer 2J.!l 2J.l.l 
25rnM MgCI2 4).ll 4).ll 
O.lMDTT ..- 2).ll 2}.11 
RNaseOUT ( 40U/J.LI) 1).ll lJ.11 
SuperScript Til RT 1 J.!l ---
DEPC-treated water 
-- 1}.11 
-
Samples were incubated at 50°C for 50 mins, the reaction terminated at 85°C for 5 
mins and then placed on ice. The sample was collected by brief centrifugation. A further 
1 ).ll E. coli RNase H (Invitrogen) was added to each sample, and then incubated for 20 
mins at 37°C. eDNA was quantified using a spectrophotometer (SmartSpec 3000, 
BIORAD) at 260 and '280nm to determine concentration. cDNAs were stored at -20°C 
prior to PCR. 
Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) amplifies a specific region of DNA between 
two oligonucleotide primers (Alberts, et al., 1996). Primers are designed in opposite 
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direction strands of DNA for amplification. The two strands of template DNA are 
denatured and separated by increasing the reaction temperature up to 94°C. The annealing 
stage is a key variable in the optimization of PCR, and allows primers to bind the 
template DNA at a temperature between 40°C and 60°C depending on the GC content and 
the sequence of the primers. Finally the extension stage at 72°C allows the DNA to extend 
from the primers (72°C). The newly synthesised DNA can now be used as a template for 
the next cycle until amplification is completed (Alberts, et al., 1996). 
CD146 primers were designed from gene Accession No. M28882.1 using Primer 3 
(GenBank, NIH) software and synthesised by Invitrogen Pty Ltd. The pri.Iner sequences 
used were: 
Fonvard: 5 '-ACCCTGAA TGTCCTCGTGAC-3' 
Reverse: 5 '-TCTCTGTGGAGGTGCTGTTG-3' ( amplicon 209bp) 
The accuracy of the primers was virtually tested using Amplify 1.2 software and 
the NCBI nucleotide-nucleotide BLAST search. 
For RT-PCR, .60 ng of each eDNA sample in 14.25 .. J.1l Milli-Q water was mixed 
with 8.75 J.1l ofPCR master mix [1.25 J.1l 50 mM MgCh, 2.5 J.li 10 mM dNTP mix, 2.5 J.1l 
10xNH4 reaction buffer (BIOLINE), 0.5 J.1l BIOTAQ Red DNA polymerase (BIOLINE) 
and 1 J.1l each of each specific primer pair]. Samples were incubated at 94°C for 3 mins 
(initial denaturation), then amplified through 35 cycles of PCR [denaturation at 94°C for 
35 seconds, annealing for 35 seconds (temperature dependent on the primer sequences), 
extension at 72°C for 35 seconds and a further extension at 72°C for 5 mins]. Products 
were maintained at 4°C when RT-PCR was completed. An RT minus eDNA sample was 
included used as a control. Amplification products were separated by electrophoresis on 
1.5% agarose gels with 1 J.1l ethidium bromide, Tracklt 1 OObp DNA ladder (Invitrogen) 
was also loaded to verify the product size. PCR results were visualised with a BioRad 
GelDoc system and WinFast software. Products were subsequently extracted and purified 
from agarose gels (JETQUICK Gel Extraction Spin, Genomed, Germany), and verified by 
dye-determination DNA sequencing of both strands (Australian Genome Research 
_ Facility, Queenland). 
Factors Involved in the Pathogenesis of Human Uveal Melanoma 49 
Western Blotting 
Western blotting was used to detect the CD146 protein in 7 uveal and 3 
metastasis-derived melanoma cell lines and primary uveal melanocytes. Cells were seeded 
in a 6-well plate (Sxl05 cells/well) and grown until - 70-80% confluent. Medium was 
removed from the well and cells were rinsed with PBS prior to protein extraction. Whole 
cell lysates were extracted by adding 350).1.1/well CellLytic-M Mammalian Cell 
Lysis/Extraction Reagent (Sigma-Aldrich Pty Ltd, Australia) supplemented with protease 
inhibitor cocktail (Complete Mini Tablets, Roche Products Pty Ltd, Australia) for 20 mins 
on a shaking table on ice. Cell lysates were collected and centrifuged for -I-s mins at 
12,000 g to pellet the cell nuclei and membranes. The protein lysates were aliquoted and 
stored at -80°C until used. 
The protein concentration of each sample was measured using the DC protein 
assay reagent kit (BioRad Laboratories, Sydney Australia). Equal amounts of protein 
(15~-tg) were used for each sample. Protein samples were mixed with Sx loading buffer 
contain 2% 2ME (2-~-Mercaptoethanol) (BioRad Laboratories, Sydney Australia) as a 
reducing agent, and ~eated at 95°C for 1 0 mins to denature the protein. Samples were 
. '· 
loaded on 10% polyacrylamide gels in the presence of sodium dodecyl sulphate (SDS) 
(Life Technologies Inc., USA). A broaQ. range molecular weight standard (BioRad 
Laboratories, Sydney Australia) was .also loaded in adjacent lanes to estimate the 
molecular weight of the bands. Proteins were separated by electrophoresis carried at 4°C 
with a constant voltage of 120V for 3 hrs. After electrophoresis, gels were placed face-to-
face with 0.45~m Invitrolon PVDF membrane Onvitrogen), sandwiched between filter 
paper and pads, and placed in the gel cassette. Cassettes were placed into the 
electrophoresis chamber filled with cold TGS buffer (Tris/Glycine/SDS, pH 8.3). Transfer 
was carried out at 4°C and 250mA (constant current) for 3 hrs. 
After transfer, the membrane was removed from the gel and washed in Milli-Q 
water, then blocked in 5% skim milk in Tween-TBS (0.05% Tween-20 in TBS ie. 
50f.,l.lll00ml TBS) at 4°C overnight. After rinsing in Tween-TBS, membranes were 
incubated in goat anti-human polyclonal CD146 antibody (Santa Cruz, diluted 1:500 in 
1% BSA and Tween-TBS) (Table 2.2a) at 4°C overnight. Membranes were then rinsed 
with Tween-TBS and incubated in perioxidase-linked secondary antibody (1 :12,500 with 
1% BSA in Tween-TBS) (Table 2.2b ). The membrane was rinsed in 6 changes of Tween-
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TBS each for 5 mins and incubated in ECL reagent (SuperSignal West Dura Extended 
Duration Substrate, Pierce Biotechnology, IL, USA) for 5 mins. To visualise the 
immunolabelling, the membrane was exposed to photographic film (X-OMAT BT film, 
Kodak) and developed. 
To confirm that equal amounts of protein were loaded in the gel, the membranes 
were incubated in Restore Western Blot Stripping Buffer (Pierce) at 37°C for an hr. The 
membrane was rinsed in two changes of Tween-TBS for 5 mins each, and incubated in 
GAPDH antibody (0.51-lg/ml with 1% BSA in Tween-TBS) (Table 2.2a) at 4°C overnight. 
After rinsing, membranes were incubated in a peroxidase-conjugated ~ti-mouse 
secondary antibody (1 :20,000 with 1% BSA in Tween-TBS) (Table 2.2b ), and viewed as 
above. Immunoblotting was repeated on 3 separate occasions. 
hnmunoblots (n=3) were analysed using a Syngene G:Box, Chemi XT 16 Camera 
and GeneSnap (Syngene) software. The average sum of intensities of CD146 bands and 
GAPDH bands for each cell line were analysed using GeneTools (Syngene) (Ver. 3.07(g)) 
software and the ratios of the average intensities ofCD146:GAPDH were calculated. 
·. 
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Immunocytochemistry 
Uveal (n=7) and metastasis-derived (n=3) melanoma cell lines and uveal 
melanocytes (n=2) were grown on coverslips and fixed for immunocytochemistry as 
described in Chapter 2.2. A polyclonal goat anti-human antibody to the extracellular 
domain of CD146 (MCAM, R&D Systems Inc, MN, USA; 2J.tg/ml) was used, with goat 
immunoglobulins (lg) (2J.lg/ml) as a non-specific control (Table 2.2a). Immunolabelling 
was visualised using rabbit anti-goat Alexa-488 conjugated fluorochrome and laser 
scanning confocal microscopy (see Chapter 2.2). 
Paraffin Sections 
Paraffin sections were cut from eyes enucleated for uveal melanoma, and normal 
eyes as described in Chapter 2.1. As mentioned previously, the specimens included 18 
untreated melanomas and 5 1125 -treated melanomas, and the majority of tumours were 
located in the choroid posterior to the equator. Normal human eyes (n=3; aged 39, 50 and 
78 years), provided by the Lions NSW Eye Bank with consent and ethical approval, were 
fixed in 10% neutral buffered formalin, paraffin-embedded, and used as controls (see 
Chapter 2.1 ). ·. 
Immunohistochemistry 
Sections were stained with polyclonal goat anti-human antibody to the 
extracellular domain ofCD146 (R&D Systems) at 2J.lg/ml in 2%NRS/PBS and visualized 
with peroxidase and Vector Red using procedures described in Chapter 2.1. 
Immunostaining of melanomas was graded in masked fashion by 2 independent 
observers using a semi-quantitative scale where 0 =none, 1 =weak (low intensity staining 
of tumour cells regardless of %, and medium intensity staining of ~20% cells); 2 = 
moderate (medium intensity staining of >20% tumour cells, high intensity stai~ng of 
~20% tumour cells), and 3 =strong (high intensity staining of >20% tumour cells). The 
grading of the 2 observers was significantly correlated (p<O.OOI; Kendall's rank 
correlation). Non-parametric linear regression analysis was used to test for an association 
between tumour histopathology and CD 146 immunolabelling, and between maximum 
tumour height (in mm) and CD146 immunolabelling. 
Factors Involved in the Pathogenesis of Human Uveal Melanoma 52 
Additionally the distribution and intensity of CD 146 immunostaining in retina 
overlying tumours, in regions of choroid and retina without melanoma as well as in 
normal choroid and retina assessed. 
·. 
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4.3 Results 
CDJ46 in Uveal and Metastasis-Derived Cell Lines and Melanocytes 
RT-PCR showed CD146 mRNA expression in all melanoma cell lines and 2 
NHM (Fig 4.1). The sequence of CD146 was confirmed by Australian Genome Research 
Facility, Queenland 
Immunoblotting showed a positive band at -130kDa for all cell lines and NHM, 
with variable levels of CD146 protein expression between samp_les (Fig 4.2A). 
~-
Membranes re-probed with GAPDH antibody showed a consistent band at ~35kDa in all 
lanes, confirming that equal amounts of protein were loaded (Fig 4.2A). The mean ratio of 
CD146 and GAPDH (from 3 separate immunoblots) showed high levels of CD146 
proteins in OCM-3, OCM-8, 92-1, Mel202, OCM-lA, NHMOI and NHM02, relatively 
less CD146 protein in OCM-1, OMM-1 and MUM2C cell lines and much reduced CD146 
protein in C918 and MUM2B cell lines (Fig 4.2B). All cell lines and NHM showed 
punctate cell membrane CD146 immunolabelling, with no inununostaining for the goat Ig 
control (Fig 4.3). 
'· 
CDJ46 in Primary Uveal Melanomas 
Overall~ grade 2 immunostaining was observed in 60% (3/5) of 1125-treated and 
78% (14/18) of untreated melanomas. For W1treated melanomas, a significant relationship 
was found between tumour cell type and average CD146 immunostaining grade (P=0.031, 
nonparametric regression; Fig 4.4), with more CD146 immW1ostaining in mixed and 
epithelioid tumours compared to.spindle cell tumours. No relationship between maximum 
tumour height (mm) and CD146 immunostaining was found for untreated tumours 
(P>0.05). As tumour specimens were collected over a recent period, the relationship 
between CD 146 expression and survival could not be analysed. 
·. 
In approximately 50% (9/18) of untreated melanomas, cells at the tumour edges 
showed moderate to strong cell membrane and cytoplasmic CD 146 immunostaining (Fig 
4.5A; insert). Within tumours, heterogeneous regions of CD146 membrane and 
cytoplasmic immunolabelling of tumour cells were observed (Fig 4.5B-E). Blood vessels 
within all tumours showed intense CD146 immW1ostaining of vascular endothelium, and 
often lumen contents (including erythrocytes) (Fig 4.5A, E; Fig 4.6A). Distinct patterns of 
CD146 immnnolabelling (Fig 4.6B), similar in appearance to PAS+ loops and networks, 
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Diagnostic RT-PCR showing CD146 mRNA expression in uveal and 
metastasis-derived cell lines and normal human melanocytes (NHM) 
(Amplicon 209bp) [Lane l=OCM-IA, 2=0CM-3, 3=0CM-8, 4=92-1, 
5=C918, 6=MUM2C, 7=RT-, 8=NHM01, 9=RT-, IO=NHM02, ll=Mel202, 
12=0:MM-1, 13=0CM-l and 14=MUM2B]. 
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Figure 4.2 
(A) Representative immunoblot showing a band at - 130kDa consistent 
with CD 146 protein expression in normal human melanocytes (NHM) 
(Lanes 1-2), uveal (Lanes 3-9) and metastasis-derived (Lanes I 0-12) cell 
lines. Reprobing of the membrane with GAPDH antibody showed a 
consistent band at - 35kDa for all cell lines. Molecular mass markers 
(kDa) are shown on the right. [Lane 1 =NHMO 1, 2=NHM02, 3=0CM-l, 
4=0CM-3, 5=0CM-8, 6=92-1, 7=Mel202, 8=0CM-1A, 9=C918, 
I O=OMM-1, 11 =MUM2B and 12=MUM2C] 
(B) Histogram of the ratio of the average intensities of CD 146 and 
GAPDH bands calculated from 3 separate immunoblots. 
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Figure 4.3 
Examples of CD146 punctate cell membrane immunolabelling of (A) 
OCM-1, (B) 92-1 cells and (C) NHM. (D) OCM- 1 cells incubated with 
control goat lg showed no immunolabelling. Cell nuclei are stained with 
Hoechst 33342 (blue). (Bar=ISJ.lm) 
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Figure 4.4 
Tumour type vs average CD 146 immunostaining grade for untreated 
melanomas (n=18; nonparametric linear regression, P=0.031). 
(A) Tumour type: (1) spindle; (2) mixed and (3) epithelioid 
(B) Average immunostaining: O=none, 1 =weak (low intensity staining of 
tumour cells regardless of%, and medium intensity staining of 20% cells): 
2=moderate (medium intensity staining of >20% tumour cells, high intensity 
staining of20% tumour cells), and 3=strong (high intensity staining of>20% 
tumour cells) (2 independent observers). 
Figure 4.5 
CD 146 immunostaining in uveal melanoma. 
(A) Low power micrograph showing CD146 expression at the tumour edge, where cells 
display membrane and cytoplasmic CD146 immunoreactivity (see insert). The more 
central regions of the melanoma (*) show lower levels of CD 146 compared to the 
tumour edge. Blood vessels (bv) jn the tumour and adjacent choroid display strong 
CD146 immunostaining. (Bar= lOO~m; Inset Bar= 30~m) (B) Grade 1 (low) CD146. 
Blood vessels show intense CD146 immunolabelling (arrows). (Bar = 35~m) (C-E) 
Areas of moderate to intense G::grade 2) cell membrane CD 146. A large blood vessel 
(bv) immunostained with CD146 is seen in (E). (C·. Bar= 35~m; D&E: Bar= 30~m) 
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Figure 4.6 
(A) CD146 immunostaining (arrows) and (C) PAS staining (arrows) oftumour blood 
vessels, with no apparent immunostaining of tumour cells. (A&C: Bar = 35).J.m) 
(B) Areas of CD 146+ networks (arrowheads) in an epithet ioid melanoma appear 
similar to (D) PAS+ loops and networks (arrowheads). (B&D: Bar = 25).J.m) 
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Figure 4.7 
(A, B) CD 146 immunostaining of retina and choriocapillaris (CC). Blood vessels 
(arrowheads) display strong CD146 expression, with both the inner and outer retinal 
vascular plexus clearly seen in melanoma-containing (A) and control (B) eyes. In (A) a 
large vessel also shows CD 146 immunoreactive perivascular cells. 
(C) No immunostaining of tumour cells or blood vessels (bv), including lumen contents, 
is seen with goat IgG control , compared to CD 146 immunostaining in the same 
specimen (0). 
(NFL - nerve fibre layer, INL - inner nuclear layer, ONL - outer nuclear layer, RPE -
retinal pigmented epithelium) (Bar = 40Jlm) 
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4.4 Discussion 
CD146 and Uveal Melanoma 
In the present study all melanoma cell lines (primary and metastasis-derived) 
expressed CD146 mRNA and protein (Western blot and immunocytochemistry). However 
C918 and MUM2B cells showed reduced levels of CD 146 protein compared to the other 
cell lines; C918 uveal melanoma cells and MUM2B metastasis-derived cells are both 
considered to be highly aggressive (Seftor, et al., 2002). Recent in vitro studies also 
described variable levels of CD 146 protein in uveal melanoma cell lines; co:n~I:uding that 
CD 146 expression was generally associated with an increased potential for in vitro 
invasiveness (Pardo, et al., 2006). Similarly, variable expression of CD146 protein has 
been reported in ovarian carcinoma cells, although associated with tumour progression, 
and poor prognosis (Aldovini, et al., 2006). Interestingly, variable gene expression has 
also been reported in uveal melanoma cell lines and in primary uveal melanoma 
specimens. CD146 was upregulated in a primary uveal melanoma cell line compared to 
two metastasis-derived melanoma cell lines (van der Velden, et al., 2003). However, 
CD146 was downre_gulated in gene arrays of Class . 2 primary uveal melanomas 
(associated with epithelioid morphology, monosomy 3 and· poor prognosis) compared 
with Class 1 uveal melanomas (spindle morphology with good prognosis) (Onken, et al., 
2005). Taken together, these studies indicate that while CD146 is involved in uveal 
melanoma growth and potential invasiveness, more than one signalling pathway may 
contribute to these processes as suggested by Pardo et al (2005, 2006). 
In primary uveal melano_mas moderate to intense CD 146 immunostaining was 
observed in heterogeneous areas, particularly more so in mixed and epithelioid 
melanomas. A major role for CD146 in the growth and metastases of cutaneous 
melanomas has been proposed, with CD 146 expression being strongly up-regulated in 
malignant melanomas of increasing vertical thickness, and particularly in metastatic 
lesions (Denton, et al., 1992~ Johnson, 1994; Kraus, et al., 1997~ Lelunann, et al., 1987, 
1989). One study has observed a correlation between CD146 expression and tumour 
thickness, associated with the transition of cutaneous melanoma from the radial to the 
vertical growth phase (Xie, et al., 1997). However, the present study found no relationship 
between CD 146 expression and maximum tumour height in this series of uveal 
melanomas. 
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Over-expression of CD146 in primary cutaneous melanoma cells has been 
reported to induce increased adhesion between tumour cells themselves, increased tumour 
cell invasiveness, as well as enhanced interactions between tumour cells and endothelial 
cells, and decreased tumour cell adhesion to laminin; these effects were reversed by anti-
CD146 (MCAM) monoclonal antibody (Xie, et al., 1997). Increased collagenase 
production was also observed in CD146 transfected cells, contributing to increased 
tumomigenicity (Xie, et al., 1997). CD146 over-expressing cutaneous melanoma cells 
induced tumour growth and metastases in nude mice that could be reversed using anti-
CD146 (MCAM) monoclonal antibody (Xie, et al., 1997). Further evidence for 
involvement CD146 in cutaneous melanoma growth comes from recenfin vitro and in 
vivo studies using antibodies to CD 146 to inhibit melanoma cell tumourogenesis and 
subsequent metastasis; a therapeutic application for CD146 antibodies in controlling 
cutaneous melanoma growth is currently being investigated (Leslie, et al., 2007; McGary, 
et al., 2003; Melnikova, et al., 2006). Although these studies indicate a major role for 
CD146 in cutaneous melanoma growth, other cell adhesion and signalling molecules, for 
example, N-cadherin, integrins, RASIERK and PI3K, are important for tumour growth 
(Meier, et al., 2005). A recent gene and tissue microarray study reported a significant 
correlation between. progression of cutaneous melanoma .~d expression of N-cadherin 
and ~3 integrin, but not CDI46 (Watson-Hurst, et al., 2006). This study did however 
implicate CD146 (and ~3 integrin) in cutaneous melanoma cell migration and invasion 
(Watson-Hurst, et al., 2006). Over-expression of CD146 has also been associated with 
tumour progression in prostate and ovarian carcinomas (Wu, et al., 2001), however, this 
may not be the case for all tumours, as seen for example in breast carcinoma where loss of 
CD 146 occurs with progression (Shih, 1999). 
Binding sites for transcription factors including activator protein (AP)-2a, Spl and 
CREB/ATF-1 have been found on the CD146 promoter (Leslie, et al., 2005). Loss of the 
transcription factor AP-2a. has been shown to be involved in progression of several 
tumours including malignant melanoma (Bar-Eli, 1999), breast and prostate 'cancers 
(Bosher, et al., 1995; Ruiz, et al., 2001) and gliomas (Heimberger, et al., 2005). Highly 
metastatic (AP-2a-negative, CD146-positive) . cutaneous melanoma (A375SM) cells 
transfected with AP-2a displayed greatly reduced levels of CD146 mRNA and protein 
compared to parental cells (Jean, et al., 1998). These cells also displayed suppressed 
tumourigenicity and metastatic potential in nude mice that was suggested to be related to 
AP-2a down-regulation of CD146 gene expression (Jean, et al., 1998). However, other 
Factors Involved {n the Pathogenesis of Human Uveal Melanoma 57 
transcription factors, including Sp 1, have been found to be involved in regulating CD 146 
expression (Karlen, et al., 1999, 2000; Mintz-Weber, et al., 2000). Regulation of other 
AP-2a.-regulated genes important for tumour cell proliferation and apoptosis, invasion and 
angiogenesis including c-kit, E-cadherin, MMP-2 and PAR-I have also been found to 
contribute significantly to cutaneous melanoma growth and metastases (Tellez, et al., 
2003). The expression of transcription factors including AP-2, Spl and CREB/ATF-1, 
their role in regulating CDJ46 and other genes, and their relationship to uveal melanoma 
phenotype and progression remains to be established. 
Soluble forms of CD146 (sCD146) have been reported in SUP-ernatants from 
cultured human umbilical vein endothelial cells (Bardin, et al., 1998). Increased sCD146 
has been found in serum from patients with several diseases including rheumatoid arthritis, 
chronic renal disease and inflammatory bowel disease, reflecting its involvement in 
endothelial cell dysfunction and vascular permeability (Bardin, et al., 2006). In the present 
study, high levels of CD146 immunolabelling were observed in endothelial cells and 
erythrocytes in uveal melanomas; although whether this immunolabelling represents 
sCD 146 remains to be established. 
CD146 in Primary Uveal Melanocytes ' • 
Normally melanocytes in skin have been reported to display little or no CD146 
(Shih, 1999). However, previous studies have shown that cultured cutaneous melanocytes 
express CD 146 protein (Shih, et al., 1994 ). In sections of normal human eyes in the 
present study, cells within the choroid did not appear to express CD146 immunoreactivity, 
although blood vessels were clearly inununolabelled. With intmunoblotting and 
immunocytochemistry, cultured primary uveal melanocytes expressed high levels of 
CD146 protein. MUC18 expression has been found to be related to the presence of 
phorbol esters (PMA) or cAMP regulators (IBMX) in glioma and carcinoma cell lines 
(Rummel, et al., 1996), both included in normal MGM used in the present study. 
Furthermore, when cutaneous melanocytes were co-cultured with epidermal keratinocytes, 
CD146 expression was down-regulated associated with E-cadherin expression (Shih, 
1999; Shih, et al., 1994). E-cadherin was the most critical adhesion molecule involved in 
mediating keratinocyte-melanocyte interactions (Shih, 1999; Tang, et al., 1994). In 
contrast, advanced and metastatic cutaneous melanoma cells do not express E-cadherin, 
and CD 146 expression on these cells was not affected by interactions with keratinocytes 
(Haass, et al., 2005; Shih, 1999; Shih, et al., 1994). Whether CD146 expression in uveal 
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melanocytes can be modulated by interactions with stromal cells (fibroblasts) similar to 
cutaneous melanocytes (discussed above )t remains to be investigated both in situ and in 
vitro . .It is also unclear whether uveal melanocytes and/or choroidal fibroblasts normally 
express E-cadherin. 
CD146 and Tumour Vasculature/Vasculogenic Mimicry 
All vascular endothelium, regardless of location or vessel size, constitutively 
express CD146 (Bardin, et al., 1996, 2001), and consistent with this, strong CD146 
immunolabelling was observed in tumour vasculature, and in retinal and choriocapillaris 
blood vessels in both control and melanoma eyes. CD 146 has been reported to be 
localized at endothelial cell junctions, although outside adherens junctions, and 
associated with actin filaments in the endothelial cytoskeleton (Bardin, et al., 2001). 
These observations suggest an important role for CD146 in endothelial cell cohesion 
(Bardin, et al., 2001; Solovey, et al., 2001). Several studies also show that CD146 binding 
in endothelial cells can regulate intercellular permeability, inducing phosphotyrosine-
kinase-dependent outside-in signaling associated with proteins including p59FYN, pl25 FAK 
and paxillin (Anfosso, et al., 1998, 2001). As mentioned previously, homotypic and 
heterotypic cell-cell interactions have been observed to be ID:~diated by CD 146, although 
the ligand remains unknown (Bardin, et al., 2001), and CD146-mediated adhesion 
between melanoma cells and endothelial cells may be important for intravasation and 
extravasation of cells in tumours (Melnikova, et al., 2006; Shih, et al., 1997; Xie, et al., 
1997). Activated peripheral T lymphocytes also express CD146, which may play a role in 
T-cell extravasation and/or homing (Pickl, et al., 1997; Seftalioglu, et al., 2000). Taken 
together, these observations suggest that interactions between CD146-positive tumour 
cells, endothelial cells and perhaps· activated T -lymphocytes may play an important role in 
melanoma (cutaneous and uveal) spread and immunoregulation. 
As described in Chapter 1.1.4, PAS+ loops and networks are correlated with more 
aggressive tumour behaviour and tend to be situated in the periphery of choroidal 
melanomas (Folberg, et al., 1993, 1996). Similarly in the present study, more peripheral 
regions of several epithelioid tumours (5/18) displayed patterns of CD146 
immunoreactivity that resembled these channels. Although it is tempting to speculate that 
- CD146 might play a role in vasculogenic mimicry in some tumours, comparison of 
CD146 and PAS-labelled serial sections, and in vitro 3D studies including use of CD146 
si RNA, would be needed to confirm this theory. The reduced levels of CD146 protein 
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expression in MUM2B and C918 cell lines also challenges the idea that CD 146 may 
participate in vasculogenic mimicry, since these cells are capable of generating these 
features in 3D culture (Daniels, et al., 1996; Seftor, et al., 2002). One possible explanation 
may be that CD146 protein expression is influenced by levels of cell confluency, although 
when 70-80% confluent cultures were compared to fully confluent cultures, no difference 
in CD146 protein expression was observed (not shown). The role of other signaling 
pathways and factors such as AP-2a in these cell lines requires further study. 
4.5 Conclusion 
Variable levels of expression of CD146 protein were observed in- uveal and 
metastasis-derived melanoma cell lines and uveal melanocytes. In primary mixed and 
epithelioid tumour specimens, CD 146 immunoreactivity was significantly greater than in 
spindle cell tumours. These observations suggest that while CD 146 is important for 
tumour growth, its expression may not be essential for invasion and metastasis, consistent 
with findings in other tumours. The role of transcription factors including AP-2 a, and the 
signaling pathways involved in regulating CD 146 expression and activity in uveal 
melanoma remain to be defined. Finally, interactions between CD 146-positive melanoma 
cells and vasculature, via an as yet unidentified ligand, may be important for the 
hematogenous spread of tumor cells during metastases. 
' 
.. 
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Chapter 5 
The Effect of Ultraviolet Radiation on Uveal 
Melanocytes and Uveal Melanom.~ Cell Lines: Cell 
Survival and Matrix Metalloproteinase Production 
Results from this study are included in tlie publication: K Lai, N DiGirolamo, RM Conway, MJ 
Jager, MC Madigan The Effect of Ultraviolet Radiation on Choroidal Melanocytes and 
Melanoma Cell Lines: Cell Survival and Matrix Metalloproteinase Production. Graefes Arch Clin 
Exp Ophthalmo/245(5):715-24, 2007 . 
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5.1 Introduction 
The role of UV exposure as a potential risk factor in uveal melanoma remains 
controversial and reviewed in Chapter 1.4. UV-B is generally considered to be the major 
photocarcinogenic component ofUV (Mitchell, et al., 1991), causing direct DNA damage, 
inducing cell death and altering expression of cell-cycle related genes and intracellular 
proteins including cytokines, growth factors and proteinases, for example, matrix 
metalloproteinases (MMPs) (Emri, et al., 2000; Kadekaro, et al., 2003; Zhang, et al., 
2003). Several studies show that UVR can induce expression ofMMPs, particularly in the 
skin (Brenneisen, et al., 2002; Enk, et al., 2006; Rittie, et al., 2002). UV-:4 and UV-B 
induce MMP-1 in both cultured fibroblasts and cutaneous keratinocytes respectively 
(Onoue, et al., 2003; Wlaschek, et al., 1994), and in vitro studies of cutaneous 
melanocytes find increased MMP-2 activity in supernatants, and enhanced melanocyte 
migration following UV-B (Wu, et al., 2004). A rapid increase in MMP-1 and MMP-10 
mRNA is also reported to be induced in a squamous cell carcinoma cell line following 
treatment with both UV-A and UV-B (Ramos, et al., 2004). In terms of ocular disease 
UVR exposure is strongly associated with cortical cataract (Delcourt, et al., 2000; 
McCarty, et al., 2000; West, et al., 1998). UV-B also .induces MMP-1 expression in 
pterygium and lens epithelial cells (Di Girolamo, et al., 2003; Sachdev, et al., 2004; 
Wlaschek, et al., 1994); however, the effect of UV-B exposure on induction of MMPs in 
human uveal melanocytes and uveal melanoma cells is not known. 
Aims 
Given the above obse!Y~tions, this study investigated the in vitro effects of UV-B 
exposure on growth, viability and MMP production in primary uveal melanocytes and two 
uveal melanoma cell lines. 
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5.2 Materials and Methods 
Cells 
As described in Chapter 2.2, OCM-1 is a spindle melanoma cell line (Kan-
Mitchell, et al., 1989) that is grown in DMEM (ThermoElectron) while OCM-8 is an 
epithelioid melanoma cell line grown in RPMI 1640 (ThermoElectron) mediwn. Hwnan 
uveal melanocytes are isolated and cultured based on the methods of Hu eta/ (1993), as 
described in detail in Chapter 2.2. 
, , 
Immunocytochemistry 
Immunocytochemical staining was performed on melanocytes and OCM-1 and 
OCM-8 melanoma cells as described in Chapter 2.2. Briefly cells were seeded on sterile 
coverslips, fixed and incubated with 10% normal goat serum (NGS). The following 
primary antibodies were used to assess the purity of melanocyte cultures: mouse anti-
human fibroblast (prolyl 4-hydroxylase) (1:25; Dako, Denmark), a-smooth muscle actin 
(1:40; pericytes, Dako), and Melanoma Ab-3 (1:100; antibodies to melanoma and 
melanocyte-specifi~ antigens HMB-45 and HMB-50, N~?Markers, USA). OCM-1 and 
OCM-8 cells were also incubated with mouse anti-swine vimentin (1: 1 00; Dako) as a 
positive control. Coverslips were incubated overnight, immunolabelled with the 
appropriate Alexa-488 conjugated secondary antibody (1 :1000, Molecular Probes, USA) 
and viewed with fluorescence microscopy. 
UV-B Irradiation 
Initially the morphology and growth of cell cultures, prior to UV-B treatment, was 
examined. To determine the most suitable cell density for these experiments, 2.5X104, 
5X104 and 105 cells/well for OCM-1 and OCM-8 cell lines were initially seeded in a 6 
well plate, and monitored by microscopy over 3 days. On day 3, wells that wer:~ seeded 
with 5X104 cells were approximately 70-80% confluent and displayed good viability; this 
seeding density was selected for further experiments (Fig 5.1 ). Melanocytes were seeded 
between 5Xl04 and 105 cells/well. 
To determine the cytotoxic dose response to UV-B, uveal melanocytes and 
melanoma cell lines were initially exposed to UV-B from 0, 10, 20 and 30 mJ/cm2 (Philips 
UV-B bulb TL 20W/1 2 RS, Sydney, Australia). UV-B light intensity was calibrated prior 
Figure 5.1 
OCM-1 (A-C) and OCM-8 (D-F) cell lines were seeded with 2.5X104, 5X104 and 105 cells/well respectively, after 3 days in culture. 
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Figure 5.2 
! 
Viable and dead cells using a 
haemocytometer chamber 
! 
Combined results 
A. Floating cells pelleted, and resuspended in 100 f.ll fresh medium. 
B. Adherent cells detached using 0.25% trypsin/0.1% EDT A, centrifuged and resuspended 
in 200 f.ll fresh medium. 
C. The number and viabi lity of both adherent and floating cell population assessed using 
Trypan Blue exclusion, and results combined. 
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Figure 5.3 
MTT assay (Roche cell proliferation kit I 1465007) for cell proliferation and 
viability measurement. 
*Adapted from Apoptosis and Cell Proliferation 2nd edition, Boehringer Mannbeim 
Figure 5.4 
A. Cultured primary uveal melanocytes. 
B. Primary uveal melanocytes, C. OCM-1 and D. OCM-8 cell lines were incubated with 
MTT reagent forming water-insoluble formazan salt (purple crystals). 
I 
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to each experiment using a radiometer IL1400A (International Light, USA). Cell 
monolayers in PBS were irradiated with the appropriate UV-B dose and changed into 
serum-free medium. Cell viability (%) was determined using trypan blue exclusion and 
hemacytometer counting. Viability of uveal melanocytes was reduced to 50% (LDSO) 
with 30 mJ/cm2 UV-B (n=2, 48 hrs after treatment). The LD50 for OCM-8 and OCM-1 
cells was 5 and 10 mJ/cm2 UV-B respectively (72 hrs after treatment). Subsequent 
experiments to measure MMP production were performed with <10 mJ/ cm2 UV-B for 
melanocytes and < 5 mJ/cm2 UV-B for melanoma cells. 
Viability and Proliferation Post UV-B 
' 
-
After UV-B irradiation, conditioned cell medium was collected at 0, 8, 24, 36, 48 
and 72 hrs in Eppendorf tubes, centrifuged for 5 mins at 1200 g and 4 oc and the 
supernatant collected and stored at -80°C for gelatin zymography (see below). The cell 
number and viability (%) of floating and adherent cells was assessed using trypan blue 
exclusion at each time point as follows. Floating cells were pelleted during collection of 
supernatants, resuspended in 1 00 J.d fresh medium, and the cell number and viability was 
assessed (Fig 5.2). Adherent cells were detached using 0.25% trypsin/0.1% EDTA for 2 
mins at 3 7°C, centrifuged for 5 mins at 290 g and 20°C, and cells resuspended in 200 ~1 
. 
fresh medium (Fig 5 .2). The number and viability of the adherent cell population was then 
determined. For each time point and treatment, the total cell number and viability was 
calculated as the floating plus adherent cell populations (Fig 5.2). 
An MTT assay was used to further assess the sensitivity of uveal melanocytes and 
melanoma cells to UV-B. MTT .assays measure the activity of viable cells based on the 
reduction of the tetrazolium salt 3-( 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MIT). This reaction produces a water-insoluble formazan salt, which must be 
solubilized and then quantified using a multiwell scanning spectrophotometer (plate 
reader) with a 570 nm filter (Mosmann, 1983). The number of viable cells is directly 
• 
• 
proportional to the amount of formazan product produced by living cells, and thus the 
absorbance reading. Uveal melanocytes (n=3, duplicate) and melanoma cells (n=3; 
triplicate) were seeded at 5x104 cells/well in ·multi-well plates, grown in serum-free 
medium as for gelatin zymography (see below) and treated with a range of doses of UV-B 
(0 to 30 mJ/cm2 for melanocytes, and 0, 2.5 and 3.5 mJ/cm2 for melanoma cells) as 
described above. Separate plates of cells were prepared for each time point, and cells were 
incubated for 24 and 48 hrs. At each time point, MTT reagent (Roche Applied Science, 
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Mannheim, Germany) was added to each well and cells incubated for an additional4 hrs 
at 37°C (Fig 5.3), followed by incubation in solubilization solution (10% sodium dodecyl 
sulfate in O.OlM HCI, Roche Applied Science) for 18 hrs at 37°C (Fig 5.4). Absorbance at 
570 nm was detected using a Bio-Rad 550 microplate reader (Bio-Rad Laboratories Inc., 
USA). Data were analysed using a non-parametric Kruskal~Wallis Conover-Inman test 
(StatsDirect Software v2.4.5). 
Gelatin Zymography 
To assess the effect of UV-B on the production ofMMP-2 and -9, melanocytes (105 
' 
cells/well) and melanoma cells (5xl04 cells/well) were initially seeded into 6-well plates 
with growth medium, and incubated at 3 7°C for 72 hrs. After removing the medium, cells 
were rinsed with PBS, then incubated in serum-free MGM, DMEM or RPMI plus ITS+3 
liquid media supplement (Sigma) respectively for 24 hrs before UV-B. After irradiation, 
conditioned media was collected at 0, 8, 24, 36, 48 and 72 hrs, centrifuged at 4 °C for 5 
mins at 160 g and supernatants aliquoted and stored at -80°C. Each time point had 
separate wells and the conditioned media was not diluted at any stage: 
Enzymatic _activity for MMP-2 and -9 in conditioned media samples was evaluated 
. . 
• 
using gelatin zymography. Samples were mixed with 5x loading buffer and run on a 10% 
polyacrylamide gel containing 1 mg/ml gelatin in the presence of sodium decyl sulphate 
(SDS) (Life Technologies Inc., USA) under non-reducing conditions. A broad range 
molecular weight standard (Bio-Rad) was run in adjacent lanes to estimate the molecular 
weight of each gelatinolytic band. Electrophoresis was carried out at 4 °C with a constant 
voltage of 120 V for 3 hrs. Gels were then washed in 2.5% Triton X-100 (BDH 
. 
Chemicals, Australia) for 1 hr at RT, and rinsed for 30 mins at RT in developing buffer 
(50 mM Tris-HCl, 100 mM NaCl, 10 mM CaCh and 0.02% (w/v) sodium azide, pH 7.5). 
Gels were placed in fresh developing buffer, incubated for 18 hrs at 37°C, stained with 
0.2% Coomassie Brilliant Blue R250 (Research Organics Inc., USA) for 1 hr at RT and 
• 
. 
destained in 10% acetic acid/ 30% ethanol for 2 hrs. Gels were incubated in gel drying 
solution (40% methanol/5% glycerol) for 1 hr and finally preserved between cellophane 
sheets. Gels were scanned and converted to Adobe Photoshop images. 
' • 
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5.3 Results 
Morphology & Immunocytochemistry of Melanoma Cells & Melanocytes 
Given the possibility that UV-B influences not only cell death but cell morphology, 
initially the general morphology of untreated cell cultures was considered. OCM-1 cells 
displayed typical spindle morphology as described previously (Kan-Mitchell, et al., 1989) 
(Fig 2.3, 5.5A). In comparison, OCM-8 cells had an epithelioid morphology, often with 
extensive processes (Fig 2.3, 5.5C). Uveal melanocytes initially displayed a bipolar 
morphology with thin processes and prominent cell bodies. However, with.!i~e in culture, 
many melanocytes extended multiple cell processes (Fig 2.4, 5.5E) and displayed variable 
melanin content (Fig 2.4, 5.5E). OCM-1 , OCM-8 cells and melanocytes were strongly 
immunoreactive for vimentin antibody, which clearly showed cytoplasmic filaments and 
general cell morphology (Fig 5.6). 
Effects of UV-B on Viability and Cell Growth 
Cell death was increased in melanoma cells for UV-B up to 20 rnJ/cm2 (Fig 5.5). 
Some OCM-1 cells'exposed to high dose UV-B also displayed irregular-morphology with 
increased numbers of processes and flattened appearance (Fig 5.5B). Melanocytes initially 
exposed to 30 mJ/cm2• UV-B showed obvious cell death when compared to untreated cells 
(Fig 5.5E&F). Trypan blue exclusion showed that melanocyte viability of did not decrease 
below 95% up to 10 mJ/cm2 UV-B (Table 5.1) while OCM-1 and OCM-8 viability had 
decreased to approximately 80% and 70% respectively at 48 hrs (Table 5.1 ). 
To further determine whether melanoma cells were more UV-B sensitive than 
melanocytes, OCM-1 and OCM-8 cells and melanocytes were irradiated and viability 
measured by MTT assay. Comparison of control and UV-B treated melanocytes showed a 
significant reduction in mean absorbance (viability) at 24 and 48 hrs for 10, 20 and 30 
mJ/cm2 (p<O.Ol; Fig 5.7). By contrast, after 48 hrs OCM-1 and OCM-8 melanoma cells 
showed significant reductions in mean absorbance (viability) for 2.5 and 3.5 mJ/cm2 UV-B 
compared to controls (p<0.02; Fig 5.7). Con.trol OCM-8 cell viability was also observed 
to be reduced with exposure to serum free medium over time (Fig 5.7). 
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Figure 5.5 
Untreated OCM-1 (A), OCM-8 (C) melanoma cells, and primary uveal 
melanocytes (E). After UV-B exposure OCM-1 (B) and OCM-8 (D) melanoma 
cells show evidence of cell death up to 20 mJ/cm2 (arrows). Many UV-B treated 
OCM-1 cells also show a flattened morphology and more cell processes (B) 
compared to untreated cells (A). In cultures of primary uveal melanocytes, dead 
cells (arrows) are seen after treatment with 30 mJ/cm2 UV-B (F). (Bar=50 Jlm). 
Figure 5.6 
OCM-1 cells, OCM-8 cells and uveal melanocytes immunolabelled with 
vimentin antibody (A-C). OCM-8 cells immunolabelled using rabbit lg control 
(D). Nuclei are identified with Hoechst 33426 (blue). 
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Figure 5.7 
Mean absorbance (± SEM) of OCM-1 , OCM-8 and melanocytes after different doses 
of UV-B treatment (mJ/cm2) measured at 24 and 48hrs using an MTT assay. 
*p<0.02, Kruskal-Wallis Conover-Inman non-parametric test for comparisons of 
control and UV-B treatments. 
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Gelatin Zymography 
Conditioned media from OCM-1 cells contained pro-MMP-2 (72 kDa) and low 
level pro-MMP-9 (92 kDa) (Fig 5.8); low levels of active MMP-2 (approximately 65 
kDa) were also detected after 48 hrs (Fig 5.8). Pro-MMP-2, MMP-9 and a faint 
gelatinolytic band at 57 kDa (possibly MMP-1) were found in conditioned media from 
OCM-8 cells (Fig 5.8). Although the levels of MMP-2 and -9 produced gradually 
increased over time up to 72 hrs for both cell lines, no differences were observed between 
conditioned media from untreated and UV-B -treated cells (Fig 5.8). Pro-MMP-2 was 
detected in conditioned media from uveal melanocytes but the -intensity of the 
gelatinolytic bands did not appreciably change up to 10 rnJ/cm2 UV-B (Fig 5.8). No active 
MMP-2, MMP-9 or pro-MMP-9 was detected in conditioned media from melanocytes 
with or without UV-B exposure. 
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Figure 5.8 
-proMMP-9 
proMMP-2 
Pro-M:MP-2 (72 kDa), M:MP-2 (65 kDa) and pro-M:MP-9 (92 kDa) in 
conditioned media from cultured melanoma cell lines (A & B) and cultured uveal 
melanocytes (C) measured by zymography. (A) & (B) are representative 
examples of OCM-1 and OCM-8 melanoma cells respectively, at time points 0 to 
72 hours after treatment, as indicated. Melanoma cell lines were treated with UV-
B at doses of 0, 2.5 or 3.5 mJ/cm2. (C) Representative zymograms for uveal 
melanocytes at two time-points, 24 and 48 hours, after treatment with UV-B 0, 
2.5, 5 or 10 mJ/cm2. 
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5.4 Discussion 
UV-B: A Risk Factor in Uveal Melanoma? 
As discussed in Chapter 1.4, the importance of UV exposure as a risk factor in the 
development of uveal melanoma remains controversial. Some epidemiological studies 
find no clear association between lifetime cumulative UV-B exposure, outdoor activities 
and development of uveal melanoma (Pane, et al., 2000; Schwartz, et al., 1997; Seddon, 
et al., 1990; Shah, et al., 2005) while other studies supported that UV-B exposure is a 
potential risk factor in the development of uveal melanoma, especially during childhood 
to adolescence (Holly, et al., 1990; Tucker, et al., 1985; Vajdic, et al., 2002). 
Although several studies have estimated the amount of UV-B received inside a 
human eye, estimates of the cumulative dose of UVR reaching the retina and choroid over 
a lifetime are extremely difficult. One study suggests that ~0.08mJ/cm2 of 300 nm UV can 
reach the lens on a given day (Sliney, 2002), with a dose of <0.8 J.l]/cm2 (<1 %) reaching 
the choroid. Without taking into physiological and external factors that further reduce 
UVR reaching the retina and choroid like orbit and eyelid structures, relative position of 
the sun and the surrounding environment (e.g. the presence of water surfaces), over 70 
years this approximates_to about 20 mJ/cm2• Clearly, the physiological cumulative dose of 
UV-B will be less than this level. Ho"Yever as a starting point to test the in vitro effects of 
UV-B on uveal melanocytes and melanoma cells growth, a single dose model of UV-B 
exposure with levels 0 to 30 mJ/cm2 was used. Other studies investigating the role of UV-
B in the pathogenesis of cutaneous melanoma and pterygium in vitro have similarly used 
an initial single dose of radiation (DiGirolamo, et al., 2003; Zhang, 2005). 
In the present study UV-B induced cell death at lower doses for melanoma cells 
(non-pigmented) than primary melanocytes. One possible explanation for this difference 
in sensitivity to UV-B is that melanin, which can absorb 400- 600 nm light (Pyyman, et 
al., 1984), may protect melanocytes against UV-B-induced damage (Kadekaro, et al., 
2003). However, even at early passages in the present study, not all cultured melanocytes 
' displayed melanin granules. Furthermore, in addition to melanin, cutaneous melanocytes 
contain pheomelanin that is reported to display photosensitizing properties (Wenczl, et al., 
1998). Uveal melanocytes also contain pheomelanin (Hu, et al., 2002) although its role in 
the response of these cells to UVR exposure remains to be determined. Taken together, 
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these observations suggest a limited role for melanin in protecting melanocytes from. UV-
B Alternatively melanocytes may be more resistant to UV-B exposure than melanoma 
cells related to the expression of genes involved in DNA damage response and cell cycle 
regulation. Consistent with this, the viability of uveal melanocytes did not significantly 
decrease with exposure to <10 mJ/cm2 UV-B treatment. 
UV-B can induce DNA damage and activate several apoptotic pathways via the 
action of p53 (Fisher, 2001), a tumour suppressor gene also reported as a risk factor in 
uveal melanoma (Coupland, et al., 2000). Cutaneous melanocytes are found to be more 
resistant to UV-B induced apoptosis than keratinocytes, related tQ the differential 
expression of several apoptotic regulators including Bc/-2 family genes (Bivik, et al., 
2005; Bowen, et al., 2003). These studies suggest that apoptosis-resistant cutaneous 
melanocytes may initially survive UVR -induced DNA changes, accumulate further DNA 
damage over time and eventually form malignant lesions (Bivik, et al., 2005; Bowen, et 
al., 2003). Whether uveal melanocytes behave similarly following low dose UVR 
exposure during the early years of life, and then accumulate DNA damage with aging to 
later progress to melanomas remains to be determined. As discussed above, cumulative 
exposure to UVR is reported as a risk factor for uveal melanoma (Holly, et al., 1990; 
Vajdic, et al., 2002), and these twnours usually grow slowly and are diagnosed much later 
in life, generally between 50 to 75 years of age (Jager, et al., 2004). 
UV-B and MMPs 
Several studies report latent MMP-1, -2, -3 and -9 expression in normal human 
choroid (Guo, et al ., 1999; Leu, et al., 2002). In the present study, isolated uveal 
melanocytes grown in serum-free medium expressed only pro-MMP-2 that could not be 
induced or activated by UV-B at doses up to 10 mJ/cm2• A recent study reported that 
choroidal and iris melanocytes cultured in serum-containing medium produced pro-MMP-
2 and low levels of MMP-9 (Chu, et al., 2004). Although gelatin zymography is a 
sensitive assay, latent or active MMP-9 could not be detected in conditioned media from 
primary uveal melanocytes in the present study. A major difference between the present 
study and that of Chu et al (2004) is the absence of serum in the culture medium. 
Cutaneous melanocytic naevi cells and lesional keratinocytes express varying 
levels of MMP-2, TIMP-2 and MTl-MMP that can be modulated by UV-B (Krengel, et 
al., 2002). In contrast overall MMP production in cultured uveal melanoma cells and 
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melanocytes increased over time independently of UV-B. However, a differential 
expression of MMPs is seen in the conditioned medium from OCM-8 cells compared to 
the less invasive OCM-1 cells (see Fig 5.7), perhaps reflecting the more invasive nature of 
epithelioid OCM-8 cells. Uveal melanomas containing epithelioid cells are generally 
associated with increased metastatic potential and a poor prognosis compared to 
melanomas with spindle cell morphology (Kansk.i, 1994). Gene expression studies 
distinguished two classes of uveal melanoma, Class 1 tumours with a spindle 
cell/melanocyte morphology and excellent prognosis, and Class 2 tumours associated with 
epithelioid morphology and metastatic disease (Onken, et al., 2004). Epithelioid choroidal 
melanomas are reported to display increased immunoreactivity for -MMP-2 and 
particularly MMP-9, compared to spindle-type tumours (El-Shabrawi, et al., 2001; 
Vaisanen, et al., 1999). A marked downregulation of TIMP-3 (MMP inhibitor) gene 
expression is also observed in the progression from melanocytes to metastasis (van der 
Velden, et al., 2003). 
As discussed above UV-B exposure is reported to upregulate MMP production by 
keratinocytes and melanocytic cells (Krengel, et al., 2002) consistent with a role for 
cellular interactions in melanocytic tumour growth. UVR-responsive cytokines produced 
by keratinoc)'Jes such as IL-l and TNF-a, are also reported to stimulate active MMP-9 
secretion in the advanced stages of cutaneous melanoma (Shellman, et al., 2006). Stromal 
cell-derived MMPs are important for _tumour growth, angiogenesis and metastasis (Jodele, 
et al., 2006), and tumour cells including cutaneous melanoma cells, are reported to 
produce factors such as extracellular matrix metalloproteinase inducer protein 
(EMMPRIN) that can induce MMP production by stromal cells (Kanekura, et al., 2002; 
Sun, et al., 2001 ). Taken together with the findings in this study, these observations 
suggest that although UV-B does not induce melanoma cells in vitro to produce/activate 
MMP-2 and -9, UVR of solid tumours such as uveal melanoma, may modulate 'MMP 
production by stromal cells in situ. To further study these interactions and the effects on 
MMP production/activation, co-cultures of uveal melanoma cells and fibroblasts 
irradiated with varying doses of UV-B could be investigated. 
5.5 Conclusion 
This is the first in vitro study to investigate the effects of UV-B exposure on the 
growth, survival and MMP production in uveal melanocytes and melanoma cells. 
Decreased survival of uveal melanoma cells, but not melanocytes, following low doses of 
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UV-B exposure suggests differences in cellular responses to DNA damage that may be 
important in subsequent transformation of melanocytes to melanomas. UV-B did not 
induce the production and/or activation of MMP-2 and -9 in melanocytes or melanoma 
cells. Future studies could investigate the expression of DNA damage response genes 
such as p53, p21 and GADD45 that can be regulated following UVR exposure, and may 
be important for uveal melanoma development, particularly with low dose UVR. 
SUOJSRf~UO~ 
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Growth and development of uveal melanoma involves both cellular and 
environmental factors. Previous studies have suggested that proteinases and adhesion 
molecules are involved in tumour growth; additionally, epidemiological studies have also 
implicated long-term UV exposure as a risk factor for developing uveal melanoma. The 
role(s) of these factors in uveal melanoma pathogenesis were more comprehensively 
investigated in this thesis. The group of primary uveal melanoma specimens examined for 
MMP-9, TIMP-3 and CD146 immunolabelling in Chapter 3 and 4, represent one of the 
larger series of tumours studied to date. 
MMPs & TIMPs in Uveal Melanoma 
The results in Chapter 3, together with observations from earlier studies (Lai, 
2002), clearly showed distinct distributions of immunostaining for several classes of 
MMPs (MMP-1, -2, -9, -19, MTI-MMP) and physiological inhibitors ofMMPs (TIMP-2 
& -3), consistent with regional differences in the tumour microenvironment seen 
histologically in uveal melanoma. The microenvironment of uveal melanoma is complex, 
including a heterogeneous population of both spindle and epithelioid cells, stromal cells 
(including fibroblast), immune cells, vasculature, gro~ factors, cytokines and matrix, all 
of which can affect uveal melanoma growth. 
Consistent with previous studies, MMP-9 was strongly expressed in most tumours 
including heterogeneous expression on tumour vasculature. Additionally, MMP-9 was 
also expressed by intravascular leucocytes; this may be important for leukocyte movement 
into tumours, and contribute to leukocyte extravasation and tissue invasion. Tumor-
infiltrating macrophages in uveal melanoma have been associated with adverse prognosis, 
epithelioid cell type and high microvascular density (Makitie, et al., 2001). Evidence of 
patterns of MMP-9 expression similar to PAS-positive networks (vasculogenic mimicry) 
was seen in some uveal melanomas; however, the involvement of MMP-9 in formation of 
extravascular channels requires further study, including three-dimensional culture 
experiments and gene profiling. 
As discussed in Chapter 1 and 3, TIMP-3 can regulate various MMPs and tumour 
invasion, as well as inhibit angiogenesis and induce apoptosis (Ahonen, et al., 1998; Qi, et 
al., 2003), and loss of TIMP-3 may be involved in tumour growth. TIMP-3 gene 
downregulation associated with changes in methylation has been recently found in various 
cancers including uveal melanoma (Mylona, et al., 2006; van der Velden, et al., 2003). In 
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Chapter 3, heterogeneous TIMP-3 immunolabelling was observed in all uveal melanomas, 
with weak expression in- 50% of specimens. Considerable variation has been reported in 
the levels and extent ofTIMP-3 immunostaining in the only two studies of primary uveal 
melanoma to date (Nareyeck, et al., 2005; van der Velden, et al., 2003). Gene microarray 
studies recently found downregulated TIMP-3 mRNA expression in Class 2 uveal 
melanomas with a poor prognosis (Singh, et al., 2007). These studies indicate that 
hypennethylation silences TIMP-3, and the therapeutic potential of agents that modify 
methylation and chromatin arrangement (such as histone deacetylase inhibitors) remains 
an area of interest for future studies. 
-
TIMP-3 may also play a role in stabilising the mature tumour vasculature by 
interacting with proteoglycans within the vascular basement membrane matrix (Chapter 
3.4). Future studies could use 3D cultures of human umbilical vein endothelial cells 
(HUVECs), co-cultures ofHUVECs and pericytes and co-cultures ofHUVECs and uveal 
melanoma cells to study the role of melanoma cell-derived TIMP-3 on vascular tube 
formation and stability. 
In conclusion, the distinct immunostaining patterns observed for MMP-9 and 
TIMP-3 within uveal melanoma are consistent with their involvement in tumour growth 
and angiogenesis. This includes expression in tumour cells; vasculature and leukocytes, as 
well as regional variations in expression that have not been described previously. Agents 
that modulate MMPs and TIMPs may be worth consideration for therapy, given that 
~50% of patients with uveal melanoma will develop metastatic disease within 10 years of 
diagnosis. 
CD146 in Uveal Melanoma 
The Ig superfamily protein CD146 is involved in tumour development and 
expressed in malignancies including cutaneous melanoma. Recent studies using 2-D gel 
electrophoresis found CD 146 expression in several uveal melanoma cell lines·.(Pardo, et 
al., 2005, 2006). In Chapter 4, the expression and distribution of CD146 in primary uveal 
melanomas was described for the first time, where CD146 immunoreactivity was found to 
be significantly stronger in mixed and epithelioid tumours compare to spindle cell 
tumours. Furthermore, variable levels of CD146 protein were observed in uveal and 
metastasis-derived melanoma cell lines and uveal melanocytes. These observations 
suggest that while CD 146 is important for tumour growth, its expression may not be 
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essential for invasion and metastasis, consistent with findings in other tumours. The role 
of transcription factors including AP-2 a, and the signaling pathways involved in 
regulating CD 146 expression and activity in uveal melanoma remain to be defined. 
Interactions between CD 146-positive melanoma cells and vasculature, via an as yet 
unidentified ligand, may also be important for the hematogenous spread of tumor cells 
during metastases. The present study further supported CD 146 involvement in uveal 
melanoma including hematogenously spread. 
As mentioned in Chapter 4.4, soluble CD146 (sCD146) has been reported in 
several diseases (Bardin, et al., 2003, 2006; Neidhart, et al., 1999) The present study 
found high levels of CD146 expression on the luminal surface of vascular endothelial 
cells and intravascular erythrocytes in uveal melanomas. To further investigate the 
involvement of sCD 146 in uveal melanoma, levels of sCD 146 in serum samples from 
melanoma patients and healthy persons, could be compared using ELISA and western 
blotting. 
CD146 also displayed PAS-like patterns in several tumours, similar to MMP-9. 
Although it is tempting to speculate whether MMP-9 and CD146 are contributing in 
vasculogenic mimicry, further studies are required to confirm this theory since uveal 
' • 
melanoma is a heterogenous tumour hence these observations might be circumstantial. 
Future experiments with in vitro 3D cultures and serial primary tumour sections might be 
able to confirm the current fmdings. · 
A Role for UV in Growth of Uveal Melanoma? 
As discussed in Chapter 5, the importance of UV-B exposure as a risk factor in the 
development of uveal melanoma remains controversial, with equivocal fmdings from 
epidemiological studies. The in vitro study in Chapter 5 is the first to investigate the 
biological effects of UV-B exposure on the growth, survival and MMP production in 
uveal melanocytes and melanoma cells. Decreased survival of uveal melanom~ cells, but 
not melanocytes, following low doses of UV-B exposure suggests differences in cellular 
responses to DNA damage that may be important in subsequent transformation of 
melanocytes to melanomas. Although UV-B did not affect the production and activation 
of MMP-2 and -9 in both uveal melanoma cells and melanocytes, it may affect other 
factors which can influence cell proliferation and survival, including cell cycle & DNA 
damage response genes such as p53, p21 and GADD45. Future studies could investigate 
-.-...· 
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the expression of these genes following UV exposure in uveal melanoma. 
Uveal melanoma is generally a slow growing tmnour, more common in older 
people, and associated with long term exposure to UV-B in earlier life. While the current 
study used a single dose of UV-B, future studies applying cmnulative doses of UV-B could 
be used to investigate regulation of both genes and proteins important in uveal melanoma 
development. These studies would also be important for discovering pathways involved in 
melanocyte-to-melanoma transformation. It is also important to understand the effects of 
UV-B on the tmnour microenvironment as described above (Chapter 6.1). One limitation 
of the present study was that the in vitro experiments were performed 01_1 either melanoma 
cell lines or primary melanocyte cultures alone. The effects of UV-B on neighbouring cells 
in the in situ environment such as fibroblasts, endothelial cells, immune cells and RPE 
would be interesting to consider . 
. .-
·. 
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